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Abstract 
 
 
 ANALYSIS OF DIFFERENTIAL GENE EXPRESSION AND ALTERNATIVE 
SPLICING IN THE LIVER AND GASTROINTESTINAL TRACT IN THE LACTATING 
RAT 
Rat exon microarrays were utilized to detect changes in mRNA expression and 
alternative splicing in the liver, duodenum, jejunum, and ileum of the lactating rat when 
compared to age-matched virgin controls.  Analysis of data at the level of gene 
expression revealed differential expression of genes involved in cholesterol biosynthesis 
in each tissue examined, suggesting increased Sterol Response Element Binding 
Protein activity.  We also detected decreased mRNA from components of the T-cell 
signaling pathway in the jejunum and ileum.  We characterized expression of solute 
carrier and adenosine triphosphate binding cassette proteins.  In addition to 
characterizing genes by pathway, we have also grouped genes based on their pattern 
of expression to identify important genes.  Amongst genes upregulated in all tissues 
was Slc39a4, which is a critical transporter in the absorption of zinc in enterocytes.  
Alternative splicing analysis detected a substantial amount of alternative splicing in the 
ileum compared to other tissues.  In addition, in the liver Abcg8, a protein that functions 
as a heterodimer to export cholesterol in the bile, shows differential splicing in the liver, 
but not in other tissues.   We also detected differential expression of Ugt1a6 in the liver 
based on usage of an alternative first exon, which is consistent with altered protein 
levels observed previously.  Differential splicing also appears to occur in Ace2 in the 
ileum, which could have consequences on the renin-angiotensin pathway.   
Multimedia formats: .jpeg, pdf 
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Chapter 1 
 
Physiology and Endocrinology of Lactating Animals 
Introduction 
 
Lactation is a time of increased energy demand, as lactating mothers must 
provide nutrients for both themselves and their offspring.  In rats, who have large 
litters, energy demand is increased four to five fold, while food intake increases 
two to three fold [1-3].  Several changes in hormone levels occur to stimulate the 
physiologic changes that take place during lactation.  Prolactin (Prl) is critical in 
the development of the mammary gland and stimulates milk secretion [4-7], and 
its levels are increased in lactation.  Thyroid hormone, leptin, and insulin serum 
levels are all decreased, possibly to maintain energy balance within the lactating 
animal by decreasing its energy expenditure.  Amongst changes seen in lactating 
rats are increased liver size [8] , growth of the small intestine [1], increased 
cholesterol synthesis [9], and increased hydrophobicity and size of the bile acid 
pool [10].  Growth of visceral tissue and improved cholesterol synthesis are also 
observed in bovines [11, 12]. 
 
In this study, we analyzed the liver, duodenum, jejunum, and ileum of lactating 
dams and compared these tissues against the same tissues in virgin controls.  
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The liver is the primary site of drug metabolism, and is also responsible for the 
production of the various components of bile, which is important for lipid 
absorption and the absorption of lipid soluble vitamins.  The small intestine is 
divided into three parts, the duodenum, jejunum, and ileum.  The three parts 
have different physiologic properties, and therefore were analyzed as three 
different tissues.  The duodenum, jejunum, and ileum as whole tissues also 
include many different cell types.  The duodenum includes Brunner’s glands, 
which are mucuous secretory cells, while the ileum contains lymph nodules 
known as Peyer’s patches [13].  Gene expression of transporters differs between 
parts of the small intestine.  For example, Abcc3 expression increases 
substantially in the ileum [14], while Abcc2 expression is high in the duodenum 
and is lower in the ileum [15-17].  A review of the expression of Solute carrier 
(Slc) and Adenosine triphosphate binding cassette (Abc) proteins in the parts of 
the small intestine can be found in Oostendorp et al [15].  These transporters can 
control oral availability of various drugs.   
Thyroid Hormone in the Lactating Animal 
 
Thyroid hormone comes in multiple forms, with 3,5,3′-L
18
-triiodothyronine (T3) being 
the form that is considered biologically active [ ].  Serum concentrations of 
thyroid hormone are decreased in lactating rats [19].  Thyroid hormone is 
required for milk secretion [7, 20, 21], and serum thyroid levels are below optimal 
for maximal secretion [7, 21].  5’ Monodeiodinase activity is increased in the 
mammary tissue, which allows for the mammary gland to locally produce active 
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thyroid hormone, permitting the mammary gland to meet energy demands, while 
conserving energy in other tissues [22].  The decrease in serum thyroid levels is 
likely to be in order to conserve energy, as thyroid hormone is strongly 
associated with energy metabolism.  The actions of the thyroid hormone are 
divided into “genomic” effects and “non-genomic” effects.  There are multiple 
forms of the thyroid receptor, which mediates the genomic effects of thyroid 
hormone, and are produced by two genes, Thra and Thrb.  In the liver and small 
intestine, Thrb is the dominant form of the receptor [23].  Microarray technology 
has been used to characterize how  thyroid hormone influences gene expression 
in cultured human fibroblasts [24], mouse brain [25], mouse liver [26-29], mouse 
osteoblasts [30], and rat liver [31].  Among genes regulated in human fibroblasts 
in response to T3 treatment is Kruppel Like Factor 9 (KLF9, also known as BTE 
binding protein or BTEB1).  Knockout of Klf9 in mice results in shorter intestinal 
villi [32].  However, Klf9 is a transcriptional repressor and may also be involved in 
inhibiting growth [33].  In addition, thyroid hormone is associated with 
mitochondriogenesis [18].  Mitochondria are the major site of energy production 
within a cell, and increasing the number of mitochondria aids in a cell’s ability to 
produce energy.  Truncated variations of isoform one of Thra and isoform one of 
Thrb (TRα1 and TRβ1), have been shown to be specifically imported into 
mitochondria, suggesting a mechanism for thyroid hormone to control 
mitochondrial gene expression [34-36].   
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Nongenomic interactions of T3 are created through interactions with various 
proteins.  One pathway that is influenced by a direct protein interaction is the 
PI3K/AKT pathway.  T3 interacts directly with PI3K, which leads to 
phosphorylation of AKT [37, 38].  The PI3Ks are a group of lipid kinases that are 
subdivided into three classes based on sequence homology [39].  These 
enzymes catalyze the conversion of phosphatidyl inositol (4,5) bisphosphate 
(PIP2) into phosphatidyl inositol (3,4,5) triphosphate  (PIP3) [40].  PIP3 can then 
be converted back into PIP2 by phosphorylates phosphatase and tensin homolog 
(PTEN), or PIP3 can phosphorylate the kinase 3'-Phosphoinositide-dependent 
protein kinase 1 (PDK1) [39, 40].  PDK1 in turn phosphorylates the protein 
product of v-akt murine thymoma viral oncogene homolog (AKT) [39, 41].  AKT in 
turn controls a large number of cellular responses, including phosphorylating the 
forkhead box transcription factors (FOXOs) and the mechanistic target of 
rapamycin (mTOR) when it is part of mTOR complex 1 (mTORC1) [41, 42].  Both 
of these processes control the ability of the cell to mobilize energy, the former by 
deactivating transcription factors, and the latter by inhibiting the ability of 
eukaryotic initiation factor 4E binding protein 1 (4EBP1) to bind to and inhibit 
eukaryotic initiation factor 4E.  Decreased 4EBP1 binding allows for additional 
protein translation.  The FOXO transcription factors control the expression of 
phophoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P), 
two of the key enzymes for gluconeogenesis [43, 44]. 
   
Leptin and insulin in the Lactating Animal 
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Leptin is a cytokine secreted by adipose tissue and aids in regulating dietary 
intake by acting on leptin receptors in the hypothalamus [45].  In general, high 
leptin levels inhibit dietary intake.  During lactation, leptin levels are low, 
encouraging nutrient uptake through increased feeding [19].  Reducing leptin 
activity reduces Adenosine Monophosphate Activated Kinase (AMPK) activity, 
decreasing β-oxidation.  AMPK is a major energy sensor for cells and plays a 
major role in control of several metabolic pathways, including downregulating 
gluconeogenesis in the liver, decreasing cholesterol synthesis by 
phosphorylating 3-Hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr), 
controlling glucose uptake in muscle by upregulating Glut4, and improving fatty 
acid oxidation and decreasing fatty acid biosynthesis by inhibiting acetyl-CoA 
carboxylase (Acc), the rate limiting step of fatty acid synthesis [46, 47].  AMPK is 
an enzyme composed of a combination of three subunits [48, 49].  The 
completed enzyme functions as an energy sensor for the cell and is regulated by 
the AMP/ATP ratio in the cell as well as multiple hormone signals [47].  Reduced 
AMPK activity also encourages fatty acid synthesis, including stimulation of Acc, 
[46], through decreased phosphorylation [47].  AMPK downregulates 
gluconeogenesis by decreasing expression of PEPCK and G6P [47].  AMPK can 
also suppress Pparγ coactivator 1α (Ppargc1α) by decreasing CRE-binding 
protein-regulated transcription coactivator 2 (CRTC2) activity [47, 50].    AMPK 
activity overlaps with several other signaling pathways, including those of insulin 
and adiponectin .  Decreased AMPK activity also encourages cholesterol 
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synthesis through decreased phosphorylation of 3-hydroxy-3-methylglutaryl-CoA 
reductase, which is the rate limiting step of cholesterol synthesis [47].  AMPK 
decreases ACC transcription through decreasing the activities of the transcription 
factors SREBP-1c and carbohydrate responsive element binding protein 
(ChREBP) [47].  Insulin, which also shows decreased levels in lactation, 
decreases expression of the leptin receptor [51].  In cows, expression of the short 
and long forms of hepatic leptin receptor increases 40% during the transition 
from late pregnancy to early lactation [51].  Leptin mediates many of its 
downstream signaling through JAK2/STAT3 activation [52].   
 
Prolactin in the Lactating Animal 
 
Prolactin is a hormone secreted from lactotrophic cells in the pituitary gland [53, 
54], and is also secreted from the mammary epithelium, placenta, brain, and 
immune system [53].  It is associated with mammary gland development and milk 
secretion.  It is closely related to growth hormone and placental lactogen, which 
are believed to all have been derived from a common ancestral gene [54, 55].  
Prl and placental lactogen bind to the prolactin receptor (Prlr), which has a long 
form, an intermediate form, and a short form in the rat [54, 56], while growth 
hormone has its own receptor [4].  Homodimerization of the Prlr in turn triggers a 
JAK2/STAT5 signaling cascade, which is considered the canonical mechanism 
for Prl signaling [4, 54].  Two JAK2 proteins phosphorylate each other and the 
activated JAK2 proteins in turn phosphorylate STAT5a.  STAT5a dimerizes and 
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transports to the nucleus, where it functions as a transcription factor and 
regulates transcription 
  
Hormones that have altered serum levels in lactation influence alternative 
splicing 
 
The decrease in insulin and leptin levels and the increase in Prl signaling during 
lactation may lead to changes in pathways that ultimately control alternative 
splicing of genes.  All three of these hormones lead to downstream PI3K 
signaling through different receptors [52, 57-61].  PI3k signaling in turn can lead 
to downstream phosphorylation of several serine-arginine (SR) proteins.  SR 
proteins control splicing events through their interactions with RNA, allowing 
recruitment of the ribonuclear proteins that perform the splicing reaction [62-64].  
SR proteins require phosphorylation to recognize the potential splice site, and 
dephosphorylation for the splicing reaction to be catalyzed [62, 65, 66].  Insulin 
signaling can trigger differential splicing of protein kinase C β II through the PI3K 
pathway and ultimately through differential phosphorylation of SRp40, a member 
of the SR family of proteins that are often involved in the regulation of alternative 
splicing [67].  Likewise, Prlr activation leads to differential splicing of neuronal 
nitric oxide synthase (nNOS) in the rat anterior pituitary cell line GH3 68 [ ].  
Consequently, differential alternative splicing through differential phosphorylation 
of SR proteins downstream of PI3k signaling seems likely in lactating animals.      
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Energy Demands of Lactating animals 
 
During lactation, many species are in negative energy balance [69].  Maintaining 
a negative energy balance can produce a state where the animal is conserving 
energy.  Both thyroid and insulin, hormones that encourage energy expenditure, 
have decreased serum levels in lactation, which is consistent with an energy-
poor state [3, 19, 70].  This negative energy balance has been proposed to be 
causative of the hypoleptinemia seen in lactation [69] and is proposed to be 
responsible for the increase in food intake during lactation [69].  However, this 
explanation does not fully account for changes in food intake or in leptin levels.  
In addition to energy demands, the suckling response has an influence on the 
diurnal regulation of serum leptin levels [69].  Also, although leptin levels may be 
reduced to compensate for negative energy balance, dietary intake does not 
increase sufficiently to  offset negative energy balance, as treatment of lactating 
rats with exogenous leptin only decreases their dietary intake by 20% [3, 69].   
Increased dietary consumption is associated with increased liver and intestinal 
growth during lactation. In ruminants, several studies indicate an increase in liver 
and intestinal growth corresponding to increased caloric uptake.  Prl was initially 
believed to be responsible for gut hypertrophy [71], as treatment with 
bromocriptine, a drug that blocks Prl release, decreases small intestinal growth.  
However, a later study directly investigating Prl showed that increased prolactin 
levels are insufficient for intestinal hypertrophy [72].    
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Zinc absorption in lactating animals 
 
Zinc (Zn+2 73-75) absorption is improved during lactation in both women [ ] and 
rats [76].  Duodenums from lactating rats display an increased uptake of 65
76
Zn.  
Duodenal zinc absorption increases throughout pregnancy and lactation and 
returns to normal levels after weaning [ ].  Zinc is an essential micronutrient 
involved in bone formation, with calcium, phosphorus and magnesium being the 
others [75].  In humans, zinc is the only one of these nutrients to continue to have 
an increased absorption rate after birth [75], although evidence exists for Prl 
improving intestinal absorption of calcium in the duodenum [77].  In lactating rats, 
Prl increases the duodenum’s ability to uptake calcium through increased 
expression of multiple transporters, including transient receptor potential vanilloid 
family members five and six (Trpv5 and Trpv6) [77].   
 
The Slc39 proteins are metal transporters.  Of these, Slc39a4 has been 
described as the primary transporter for intestinal uptake of zinc, and failure to 
produce a functional form of this protein in humans leads to a disease state 
known as acrodermatitis enteropathica [78].  There is an alternative mechanism 
for zinc uptake.  Although this mechanism is not well understood, the primary 
method for treatment of acrodermatitis enteropathica is a high zinc diet.  Because 
lactating animals have improved zinc absorption, one of these mechanisms may 
be improved in the lactating dam.  Mechanisms controlling expression of Slc39a4 
are poorly understood, but another zinc transporter in the same family, Slc39a1, 
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is upregulated in response to Prl treatment in prostrate-derived cancer cell lines 
[78, 79].   
 
Changes in the bile acid pool in lactating dams 
 
The hepatocyte produces bile acids, which function in the intestine to solubilize 
cholesterol and other lipids and facilitate their absorption.   The bile acid pool size 
and its hydrophobicity are increased in lactation.  During a time course study 
over days of lactation, a statistically significant increase in the bile acid pool size 
is first noticed on day 10 of lactation [10].  A shift in the diurnal rhythm regulating 
Cyp7a1, the rate limiting step of bile acid synthesis, and a significant increase in 
Cyp7a1 transcription occurs at 16 h when compared against age matched virgin 
controls.  No such increase was detected in Cyp27a1, suggesting that the 
primary mechanism for increased bile acid pool size is an increase in Cyp7a1 
activity.  The increase in transcription occurs alongside increased recruitment of 
LXRα to the Cyp7a1 promoter, possibly through increased availability of LXR 
substrate in the form of cholesterol [80].  Decreased repression of Cyp7a1 
transcription plays a role in Cyp7a1 upregulation during lactation.  Expression of 
Fibroblast growth factor 15 (Fgf15) is downregulated in the ileum in lactation, 
leading to decreased extracellular signal related kinase 1 and 2 (Erk1/2) 
phosphorylation, as shown by the 88% decrease in phosphorylated Erk1/2 in the 
liver of lactating rats [80].Coupled with the knowledge that in primary human 
hepatocytes, FGF19, the homolog of Fgf15, inhibits CYP7a1 through the ERK1/2 
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pathway [81], these data provide a likely mechanism by which Cyp7a1 
expression is increased in the liver of the lactating dam.     
 
Changes in bile acid transport in lactating dams 
  
In addition to the increased production of bile acids, expression of the bile acid 
transporters Abcb11(Bsep), Slc10a2 (Asbt), and Slc10a1 (Ntcp),  is also 
upregulated.  Bile acids are synthesized in the liver, exported into bile through 
Abcb11, taken into the enterocyte by Asbt, transported into the portal circulation 
by Ostα/β, and then taken back up in the hepatocyte by Ntcp.  Abcb11and Ntcp 
show a significantly increased level of protein relative to virgin controls on day 2 
post partum as a response to Prl, as shown by treating rats with Prl and 
measuring resulting Ntcp and Abcb11 levels [82].  The increase in Ntcp mRNA 
and protein can be directly linked to increased JAK/STAT5 signaling at a Stat5 
response element at -1237 to -758 bps in the Ntcp promoter and is mediated by 
the long form of the Prlr [83].  Ntcp shows a two fold increase in protein and a 1.7 
fold increase in Vmax for transport of taurocholate at day two post-partum, and 
the increase in expression and protein is maintained for two weeks [82].   
Regulation of Asbt appears to be posttranscriptional, as levels of Asbt mRNA are 
not different between control and post-partum day 14-21 rats despite increased 
Asbt protein expression [84].  Bile flow, which is generated by secretion of bile 
salts, is essential for the biliary secretion of cholesterol and many xenobiotics, 
and is increased in lactating rats [8, 85].  Bile flow, bile acid secretory rate, and 
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hepatic clearance of taurocholate in response to taurocholate infusion was 
shown to be mediated by Prl [8].  
 
 
Increased cholesterol synthesis in lactating animals 
 
Cholesterol biosynthesis is increased in both the small intestine and the liver 
during lactation.  This was initially shown by an increase in incorporation of 
tritiated water into newly synthesized cholesterol [9].  At day 14 postpartum, a 
significant increase in cholesterol synthesis was detected per total organ in both 
the small intestine and liver in lactating rats when compared against nonlacting 
postpartum rats.  3-Hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr) 
shows increased activity in the liver of lactating rats sacrificed at 10:00 and 14:30 
on day 10 post-partum compared to age-matched virgin controls [86].  Because 
cholesterol biosynthetic enzymes are all sensitive to SREBP-2 activity [87, 88], 
one possible mechanism is that SREBP-2 activity is increased during lactation in 
these tissues.  A similar trend has also been observed in the mammary gland 
[89].  Increased amounts of cholesterol are essential in lactation, due in part 
because it is needed for incorporation into the milk for growth and neural 
development in the pups.  However, cholesterol is also required for bile acid 
synthesis, which is also increased in lactation.  As indicated above, bile acids are 
required for efficient intestinal absorption of cholesterol, lipid, and lipid-soluble 
vitamins [90]. 
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Cholesterol synthesis and lipogenesis are controlled by three transcription 
factors, known as Srebps, which are made by two genes, the Srebfs.  The Srebf1 
gene codes for the transcription factors Srebp-1a and Srebp-1c, while Srebf2 
codes for the protein Srebp-2.  The three proteins differ in their ability to regulate 
the processes of lipid synthesis and cholesterol biosynthesis, but there is overlap 
between the target genes [87, 88].  Srebp-1a is more closely associated with 
fatty acid synthesis, while Srebp-2 is more closely associated with cholesterol 
biosynthesis, as shown in mice expressing dominant positive forms of the two 
proteins [88].  The rate limiting steps of the two processes, Acetyl-CoA 
carboxylase (Acaca or Acc) for fatty acid synthesis, and HMGCR for cholesterol 
synthesis, are shown to be upregulated in mice expressing the dominant positive 
form of Srebp-1a and Srebp-1c, as well as downregulated in Srebp chaperone 
(Scap) knockout mice [87].   
 
The Srebps share a common mechanism for activation [91].  Under conditions of 
sufficient cholesterol concentrations, the protein product of insulin stimulated 
gene (Insig) is bound to cholesterol, and keeps an Insig/Scap/Srebp complex 
sequestered in the endoplasmic reticulum.  When not bound to cholesterol, Insig 
is degraded, freeing Scap to escort the Srebp to the Golgi where it is cleaved and 
activated.  The N-terminal of the Srebp protein can then travel to the nucleus, 
where it functions as a transcription factor and stimulates the production of target 
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genes, including genes involved in fatty acid synthesis and/or genes involved in 
cholesterol biosynthesis [91]. 
 
Microarray analyses of various models have identified several potential 
downstream targets of Prl [53].  Amongst these targets is Srebf1, which codes for 
the Srebp1a and Srebp1c proteins.  The protein products of Srebf1 are strongly 
associated with controlling fatty acid and cholesterol biosynthesis [87].  Srebf1 is 
consistently downregulated in three different models of Prl deficiency, indicating 
that Prl can control transcription of Srebf1 [53, 92].  Due to the increased need of 
the lactating dam for both fatty acids and cholesterol, the activity of all three 
Srebp proteins may be improved.  
 
 
Changes in cholesterol and phospholipid transport into bile in lactation 
 
Components of bile include cholesterol and phospholipids, in addition to bile 
acids.  While Abcb11 transports bile acids into bile, Abcg5 and Abcg8 function as 
a heterodimer to transport cholesterol, and Abcb4 (Mdr2) transports 
phospholipids into bile.  mRNA expression of Abcg5 and Abcg8 in liver 
decreases over 90% throughout lactation [93], and despite this loss of 
Abcg5/Abcg8 in expression in liver there is no change in the cholesterol or 
phospholipid concentration in bile during lactation.  However, following infusion of 
taurocholate, increased secretion of cholesterol was impaired relative to controls 
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indicating a decreased coupling of taurocholate and cholesterol excretion into 
bile [93].  Western analysis does not detect Abcg8 protein in the livers of lactating 
rats [93].  The decreased presence of function Abcg5/Abcg8 dimer uncouples 
taurocholate and cholesterol transport into bile and could provide a mechanism 
for retention of cholesterol while the lactating dam is in a physiologic state that 
requires more cholesterol [93] 
 
The Ugt1a Locus in Lactation 
 
The UDP glucuronosyltransferase (Ugt) superfamily of proteins is responsible for 
transferring glucuronic acid to their respective substrates in order to form water 
soluble molecules that are often biologically inactive and are subsequently 
excreted into urine or bile [93].  The Ugt1 gene associated with these proteins 
generates several possible proteins based on usage of an alternative first exon 
and common exons 2-5 [93].  In transgenic mice expressing the human form of 
the UGT1A locus, UGT1A4 and UGT1A6 expression are both elevated during 
lactation [93].  In rats, protein and mRNA levels of Ugt1a6 are increased in the 
liver, and its expression is also increased by treatment of rats with Prl, 
suggesting that Ugt1a6 expression is sensitive to Prl levels [94].  These data 
provide the rationale for studying expression of the alternative exons in the rat 
Ugt1a locus.  The Affymetrix Rat Exon 1.0 ST array (Affymetrix, Santa Clara, CA) 
provides probes that interrogate these exons, and consequently allow for 
detection of differential expression of the various mRNAs produced by the Ugt1a 
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locus.  Substrates of Ugt1a6 include phenols such as acetaminophen, and 
consequently Ugt1a6 is important in drug metabolism in the lactating animal [95].   
 
Rationale 
 
In light of the large number of physiologic changes that occur in lactating animals 
relative to virgin animals of the same species, characterization of every 
transporter, enzyme, hormone, and transcription factor that has altered 
expression during lactation would be inefficient, time consuming, and expensive.  
Characterization of the transcriptome of the lactating animal allows a better 
understanding of the ability of lactating animals to absorb and metabolize 
nutrients and respond to changes in hormone levels.  Understanding the 
transcriptome can in turn lead to hypotheses regarding mechanisms of how 
lactating animals absorb key nutrients, synthesize important metabolites, and 
respond to altered levels of hormones in serum.  Here, we utilized the Affymetrix 
Rat Exon 1.0ST exon chip to characterize mRNA expression and differential 
alternative splicing in tissues from day 10, 16 h lactating rats compared to age-
matched virgin controls.  Day 10, 16h lactating rats were chosen because this is 
the first time point at which a statistically significant increase in expression and 
activity of Cyp7a1, the rate limiting step of bile acid biosynthesis, is observed 
[10].  The microarray analyses should support our previous results regarding 
expression of key enzymes, such as Cyp7a1, in bile acid and cholesterol 
synthesis as well as transporters important for their transport into bile [10, 93], in 
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addition to providing insight into their mechanisms of regulation.  Finally, new 
information regarding expression and regulation of additional pathways important 
for changes of biological importance in the lactating dam should be discovered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Antony Athippozhy 2011
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Chapter 2 
Microarray Design 
Analysis of Microarray Data 
While technology now exists for high throughput analysis of large biological 
datasets, biological systems are extremely complicated and require advanced 
techniques to mine and interpret the data.  For example, microarray technology 
allows for the measurement of most RNAs within a given sample.  Bioinformatics 
is the field of study in which “information sciences” such as computer science 
and statistics are utilized to interpret biological data.    
Microarray technology is based on nucleotide hybridization methods.  
Oligonucleotide probes are utilized to detect the presence of cDNA synthesized 
from RNA samples and tagged with a fluorescent dye.  Original microarrays 
utilized probes designed for the 3’ ends of genes and were utilized for the 
estimation of overall gene expression.  Newer designs can contain probes 
designed to span an entire transcript.  These arrays also allow the estimation of 
differential alternative splicing between different experimental conditions.  
Affymetrix is a supplier of chips utilizing oligonucleotide probes synthesized in 
situ on a glass plate.  For simplicity’s sake, data analysis will be discussed with 
respect to the Affymetrix platform, but many of the same concepts are applicable 
to other platforms.  
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Pooling 
Microarray chips can be expensive when compared to the cost of individual 
biological samples.  Consequently, one method to circumvent the cost of a 
microarray experiment is to combine mRNA/cDNA from several samples to 
reduce the variance between individual chips.  As more samples are pooled, the 
mRNA/cDNA concentration for a given gene approaches the population average 
for the new pooled sample, reducing the effect an individual rat would have on 
the measurement of gene expression.   Power calculations demonstrate that 
increasing the number of samples pooled and loaded onto a chip can give similar 
power to that obtained by running a larger number of arrays.  In an experiment in 
which p samples are mixed, the number of arrays needed to obtain a similar 
power in the absence of pooling is approximately 1/p, assuming a large number 
of samples [96].  Therefore, an experiment utilizing six chips, each containing 
mRNA from five individual samples would be comparable in statistical power to 
an experiment containing thirty individual samples.  
Preanalysis Data Treatment 
When fluorescence intensities are initially measured from the array, a number of 
biases exist that are independent of the biological sources of variance [97].  For 
example, a difference in lighting on individual chips would lead to a chip effect 
that could influence interpretation of the results.  Consequently, a number of pre-
analysis steps are required to convert the fluorescence intensities into data that 
have biological relevance.  These steps usually include a background correction 
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step, a normalization step, and a transformation step, as described below.  One 
commonly used method for performing these tasks is the Robust Multichip 
Averaging (RMA) method, although other techniques exist. 
The first step in adjusting the data is background correction.   Affymetrix originally 
utilized intentionally mismatched probes at the thirteenth nucleotide in a 25mer 
oligonucleotide probe to determine amounts of nonspecific binding.  However, 
this method was found to not be effective, as the measured intensity of the 
mismatch probe was found to increase as the intensity of the perfect match 
probe increased [98], suggesting that the mismatch probe had specific affinity for 
the target sequence. One method to circumvent the usage of mismatch probes is 
to assume that the background is based on random error, and calculate it from 
the standard deviation of perfect match signals, as is done in RMA.  The RMA 
background correction assumes that the observed signal is produced as the sum 
of the actual signal from the bound target and random error.  The bound target 
signal is assumed to be exponential and the error is assumed to be normally 
distributed.  A description of the normalization procedure can be found at 
http://bmbolstad.com/misc/ComputeRMAFAQ/ComputeRMAFAQ.html.  
Normalization is performed in order to make each chip comparable by removing 
nonbiological effects and allows for measurements on separate chips to be 
comparable to each other.  The RMA algorithm utilizes quantile normalization 
[99].  In this method, probe intensities are ranked for each chip.  Then for each 
rank (e.g., the highest, 50th highest, 100th highest, etc), the average across all 
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chips is taken, and the corresponding values are all set to the average.  This 
forces the distribution of measurements on all chips to be equal [100].   
The final steps toward getting the data into a workable format are 1) log2 
transformation of the intensities allowing for the use of parametric statistical tests 
by adjusting the distribution of the measurements, and 2) summarizing the 
intensity values of individual probes into a single measurement for the 
corresponding exon or gene.  In RMA, Tukey’s median polish [99] is utilized to 
summarize the data, but other methods such as Tukey’s biweight have also been 
utilized [99]. 
Detection of Differential Gene Expression 
Once the data between each individual microarray chip is comparable to data 
from the other chips, a method of analysis needs to be chosen.  Early microarray 
experiments utilized a fold-change approach.  The problem with this approach is 
that it only compares the means of a given gene’s expression between two 
groups, and not the variance within those measurements.  Consequently, this 
method does not allow for the calculation of the likelihood of a false positive.  
Correcting for the likelihood of false positives within the experiment is discussed 
in the “Multiple Testing in Microarray Data” section below.   
Either a parametric or nonparametric approach can be chosen to identify 
differentially expressed genes.  The nonparametric approach makes no 
assumptions about the distribution of the data, but at the loss of statistical power.  
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The parametric approach requires that the data being tested be approximately 
normally distributed.  ANOVA and Kruskal-Wallis tests have been frequently 
used in microarray datasets to detect differential gene expression. 
We have studied a system in which lactating rats were compared against age-
matched virgin controls.  We analyzed four tissues from each rat and pooled 
RNA from the same tissue from four rats within the same physiologic state 
(control or lactating).  The pools of four rats were consistent between tissues.  In 
other words, if rats 1,2,3, and four composed pool one in the liver, the same four 
rats would compose pool one in the duodenum, jejunum and ileum.  This led to a 
two-way, mixed models, repeated measures experimental design.  Mixed models 
approaches can be utilized when multiple samples are taken from the same 
subject.  In this case, the four tissues were all taken from the same sets of four 
rats.  This led to a design in which we had two fixed effects (tissue and 
physiologic state) and one random effect (the subject variable, which in this case 
is a set of four rats.)  A mixed model is comparable to the corresponding linear 
model, except that the model is now expanded so that each term contains a 
matrix that accounts for the individual samples.  Accounting for the presence of 
the individual subjects also generates a second error term that accounts for 
differences between unique samples and is based on the covariance matrix.  
This means that a method for approximating the covariance matrix must be 
applied. One method, known as compound symmetry, was to assume that all 
covariances are equal. 
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Multiple Testing in Microarray Data 
Due to the large size of a microarray data set, multiple tests have been 
performed in order to detect changes in gene expression. Two types of error 
could be made, rejecting the null hypothesis (measurements are made from the 
same distribution) when it should not have been rejected (Type I error, or a false 
positive) and failing to reject the null hypothesis when it should have been (Type 
II error, or a false negative). Although the probability of any given test producing 
a type I error (alpha) is small, the probability that a false positive exists within the 
entire data set, (the family-wise error rate) may still be very high.  There are 
several ways to correct for this.  One of the earliest methods to correct for 
multiple testing was the Bonferroni procedure [101].  However, this test is 
extremely conservative, and leads to a very small list of differentially expressed 
genes.  A second approach is to correct for the family-wise error rate (FWER) 
[101].  This method attempts to control the probability that a false positive 
appears anywhere in the dataset.  However, because of the exploratory nature of 
many microarray studies, this test is still overly conservative, as many 
experimenters would be willing to accept the existence of a few false positives 
within the dataset.  The false discovery rate (FDR) method attempts to fix the 
ratio of false positives to total positives in a given dataset [102].  The Benjamini-
Hochberg procedure for calculating false discovery rates lets p1,p2,…pm be the 
rank ordered p-values, where m is the total number of tests.  [All hypotheses 
where pi 102<iα/m are rejected [ ], where i is the i’th ranked p value and α is the 
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cutoff value for the FDR.]   A common cutoff for the FDR is 0.05, but even this 
may be too conservative for some studies.  An alternative to fixing the FDR is to 
fix a set p-value cutoff, and calculate what the FDR or proportion of false 
positives (PFP) is at the given p-value.  The challenge in choosing an appropriate 
cutoff is that as the probability of a type I error decreases, the probability of a 
type II error increases.  Note that although the Benjamini-Hochberg [102] method 
was the first described to control the FDR, other methods exist [101].  Here we 
set the p value cutoff threshold and calculated the PFP. 
Detection of Trends and Pathways in A List of Differentially Expressed 
Genes 
Once a list of differentially expressed genes has been generated, the 
experimenter must determine which genes are of particular interest.  Given a list 
of the differentially expressed genes and a database that organizes these genes 
into various categories (for example, organizing genes by pathway or function), a 
test can be performed to identify whether a given category is overrepresented in 
this list of genes.  Several methods exist for detecting overrepresented groups of 
differentially-expressed genes [103].  One method is to utilize a right-tailed 
Fisher’s Exact test to identify the probability that a number equal to or higher than 
the number of genes actually detected within a group would appear by chance 
[104].  This method is utilized by DAVID [104, 105] and Ingenuity Pathways 
Analysis (IPA) (Ingenuity Systems, www.ingenuity.com).  Because a test is 
performed for each category of genes, multiple testing is an issue, and a multiple 
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testing procedure such as the FDR can be applied to correct for the possibility of 
a high number of type I errors [104]. 
Analysis of differential alternative splicing provides many additional challenges.  
On an Affymetrix exon array, the probes on the array are divided into probesets, 
which correspond to regions of a transcript.  For the purposes of analysis, the 
probesets are each treated as independent exons, although large exons are 
often assigned multiple probesets.  Based on the source of information Affymetrix 
utilized to design the probes, Affymetrix assigns each probeset to a “confidence 
level”.  “Core” probesets are regions that are drawn from a curated database 
such as Refseq.  “Extended” probesets are derived from expressed sequence 
tag (EST) databases.   “Full” probesets are derived from software predictions.  
There are 92,354 probesets at the Core confidence level on the Affymetrix Rat 
Exon 1.0 ST array.  Consequently, a large number of exons could test positive by 
chance, and multiple testing is problematic.  The Benjamini-Hochberg approach 
has been applied to address this issue [106], and is readily available in software 
packages, but to our knowledge, the multiple testing issue has not been 
addressed specifically for exon arrays.   
Detection of Differential Alternative Splicing 
After performing a data treatment algorithm such as RMA, data can be 
summarized at both the probeset and transcript level.  Summarizing data at the 
probeset level permits analysis at the exon level.  However, a large difference 
between intensities of a given probeset is not sufficient for identifying 
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differentially alternatively spliced transcripts.  Although a specific probeset may 
display differential expression, the transcript itself may be differentially 
expressed.  Consequently, determination for whether or not a specific treatment 
triggers differences in alternative splicing must take into account differences in 
mRNA expression.   
Affymetrix arrays lack junction-specific probes, and therefore methods designed 
for detecting alternative splicing using this information is invalid.  Three of the 
methods that do not take into account this information are Analysis of Splicing 
Variance (ANOSVA) [107], Microarray Dectection of Alternative Splicing (MiDAS) 
[97], and Finding Isoforms from Robust Multichip Analysis (FIRMA) [108].   
Affymetrix proposed the MiDAS method as a means of detecting differential 
alternative splicing between multiple groups.  In this method, probeset intensities 
are divided by transcript level intensity to create a gene-normalized intensity.  
Then, a statistical test (an ANOVA, if done as originally proposed by Affymetrix) 
is utilized to determine differences in gene-normalized intensities between 
treatment groups.  The first problem to address is that without adequate filtering, 
every exon in the dataset is tested at least once for alternative splicing.  This 
leads to a very high number of statistical tests, and the problem of multiple 
testing becomes substantial, especially if the treatment triggers a relatively small 
number of changes in differential splicing when compared to the entire dataset.  
The second is that the calculated transcript level intensity needs to be accurate, 
because the algorithm is dependent on using the transcript level estimate to 
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normalize all probesets within that transcript.  This can be particularly 
problematic in a gene that has a large number of splicing events, since the 
transcript level measurement is summarized from the probeset level 
measurements (even if in principle, the individual probes are treated separately 
for the purposes of summarization.)  Reports exist stating that the distribution of 
p-values resulting from MiDAS are not normally distributed in the non-significant 
range [109]. 
The ANOSVA method utilizes a linear model to determine if differences in 
alternative splicing occur between groups.  The model follows the form of 
yijkl=μ+αi+βj+γij+error, where the error is normally distributed around mean zero 
and random, μ is the baseline intensity, αi is the “exon effect”, βj is a “treatment 
effect”, and γij is the interaction term between αi and βj.  The interaction term 
(treatment*exon) is utilized as a means of determining if a transcript is 
differentially alternatively spliced between treatment groups [107].  A significant 
interaction term is determined to be a positive test.  This conclusion operates 
under the assumption that if a probeset’s intensity is not the sum of random error, 
the treatment effect, and the individual exon effect (which can also be considered 
as a probe affinity term) then the difference must be caused by differential 
alternative splicing.  A significant interaction is graphically visible by plotting 
intensities as a function of exon for all treatment groups.  In the absence of an 
interaction term, the intensities for each group will be parallel when plotted as a 
function of the individual probesets (Figure 2.1).  This can be seen in that the 
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intensities of both control and lactation are parallel for Abcg5 in the ileum, but in 
Ace2 there is a point where the two lines were not parallel, indicating possible 
alternative splicing at that point.  However, there are a number of situations 
where events other than differential alternative splicing cause a significant 
interaction effect.  This will lead to false positives, and because the underlying 
assumptions regarding what is defined as alternative splicing are violated, even a 
transcript with a low interaction p-value may be a false positive under certain 
circumstances.  These circumstances are discussed below.   
FIRMA is a method based on utilizing the RMA algorithm.  The model 
(PMik)=ci+ρk+Є ik, is utilized to calculate residuals for each individual probe, 
where PMik is the measured intensity from the probe, ci is the chip effect 
(expression level), pk is the probe effect (or probe affinity), and Єik
108
 is the random 
error [ ].  The median residual (the difference from the mean) divided by the 
standard deviation is used as a score to identify exons that are differentially 
spliced.  Unfortunately, a good guideline for a significance cutoff based on 
FIRMA scores has not been developed [108].     
A number of events can occur that will lead to false positives.  The first is the 
absence of either a gene that is not expressed in a treatment group, or an exon 
that is expressed in no treatment groups.  Because the methods for detection are 
based on the relative expression of a probeset relative to the gene, the absence 
of a probeset in both groups or the absence of the gene in one group lead to 
false assumptions in the algorithm.  In order to filter out poorly expressed 
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probesets, Affymetrix has developed the Detection Above Background Algorithm 
(DABG) algorithm [110], as exon arrays do not have single nucleotide mismatch 
probes.  In this method, background probes of random sequences of the 26 
possible GC contents for a 25-mer oligonucleotide sequences are measured.  
These probes are used as a background for probes of the same GC content.  
Probesets with a DABG p-value of less than 0.05 can be considered present at 
above background levels, although making the threshold more stringent is 
possible. No method for specifically determining the presence or absence of a 
given gene has been developed, so genes have a presence/absence call based 
on the exons within the same transcript [97]. 
Cross-hybridization can also be problematic.  In the presence of cross-
hybridization, an increase in measured intensity will appear, and the 
measurement may often be higher than constitutively expressed exons.  
Affymetrix recommends eliminating measurements that appear at a much higher 
or much lower intensity than other probesets in the gene. Removing highly 
expressed probesets is not problematic, as the intensity appears higher than 
other constitutively expressed exons.  However, removing poorly expressed 
exons is problematic, as it is difficult to tell whether poor expression is caused by 
poor hybridization or by only a fraction of the transcripts in fact containing 
sequences corresponding to the probeset of interest, in which case the exon 
positive test is detecting differential alternative splicing.    
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Another risk is if the probe sequences are annotated incorrectly.  Affymetrix 
assigns each probeset a “confidence level” based on the line of evidence utilized 
to identify the transcript associated with the probes.  Selecting to analyze genes 
only at the “Core” confidence level reduces the chance of misassignment. 
A final potential problem Affymetrix warns about is extremely low variance across 
a specific probeset, since the low variance could be mediated by an event such 
as the probe not hybridizing to the target sequence.  Affymetrix does not 
recommend a specific filter for identifying regions with excessively low variance, 
but the possibility of an exon showing low variance for reasons independent of 
alternative splicing should be taken into account.  
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Figure 2.1: Genes that test negative (Abcg5 top) and positive (Angiotensin 
converting enzyme 2, bottom) for alternative splicing in the ileum.  Chromosome 
position is plotted on the x-axis, chromosome number is listed on the left y-axis, 
and probeset intensity is plotted on the right y-axis.  Note that for the gene 
(Abcg5) that tests negative, the exon intensities appear to be parallel between 
control and lactating groups as a function of chromosome position, while this is 
not true for the gene (Ace2) that tests positive.  Along the top of each figure is the 
gene and its corresponding refseq entry, with the boxes representing individual 
exons.  Both Abcg5 and Ace2 are annotated as being on the minus strand.  In 
order to show both strands, Partek draws genes on the minus strand with the 5’ 
end on the right and the 3’ end on the left. 
 
 
 
 
 
 
 
 
 
© Antony Athippozhy 2011 
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Chapter 3 
 
Differential gene expression in liver and small intestine from lactating rats 
compared to age-matched virgin controls detects increased mRNA of 
cholesterol biosynthetic genes 
 
Background 
  
Lactation is a time of a four- to five-fold increased energy demand imposed by 
the suckling young that requires a proportional adjustment in the ability of the 
lactating dam to absorb nutrients and to synthesize critical biomolecules to meet 
the dietary needs of both the offspring and the dam [1-3].  Lactating rats have a 
two- to three-fold increase in food consumption (hyperphagia) [1-3], in part 
through the decreased suppression of appetite accompanying decreased serum 
leptin [19]. 
 
Diet and hyperphagia have been shown to influence the rate of cholesterol 
synthesis, which is increased in the liver and small intestine in the lactating rat [9, 
111].  Of these tissues, the liver is the primary contributor to serum levels of 
cholesterol, and shows a quantitatively greater increase in the rate of cholesterol 
synthesis during lactation [9].  3-Hydroxy-3-methylglutaryl-coenzyme A reductase 
(Hmgcr), the enzyme catalyzing the rate-limiting step of cholesterol synthesis, 
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shows significantly increased activity in the liver during lactation compared to 
virgin and nonlactating control rats [86, 112].  Cholesterol synthetic and lipogenic 
genes are regulated by transcription factors termed sterol regulatory element 
binding proteins (Srebp); the activity of Srebp proteins is in turn regulated by the 
Srebf chaperone (Scap) and the Insulin induced genes (Insig).   
 
Circulating serum levels of several hormones that regulate metabolism are 
decreased during lactation in the rat, including thyroid hormone, insulin and leptin 
[19].  Such changes in hormone signaling and diet are likely to have large 
influences on the activation of their corresponding pathways.  Receptors for 
leptin, thyroid hormone, and insulin are expressed in both the liver and small 
intestine [23, 113-117], with liver being considered a major site of insulin 
signaling [113] and thyroid receptor β (TRB, Thrb) being the dominant form of the 
thyroid receptor in both tissues [23].  Leptin acts on the small intestine and 
inhibits sugar uptake [115], and the liver is a major source of the soluble form of 
the leptin receptor, particularly under conditions of negative energy balance 
[116], as occurs in lactation [3].  Therefore, altered serum levels of these 
hormones would be expected to influence mRNA expression of downstream 
genes.    
 
Our laboratory has been investigating the effects of lactation on the synthesis 
and transport of bile acids in the liver and small intestine in the rat [10].  Bile 
acids are synthesized in the liver from cholesterol, and are essential for the 
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biliary excretion of cholesterol and for the efficient intestinal absorption of 
cholesterol, lipid-soluble vitamins and lipids [90].  Bile acids are secreted into bile 
by the Bile salt export pump (Bsep; Abcb11), taken up across the apical 
membrane of the enterocyte in the terminal ileum by the Apical sodium-
dependent bile acid transporter (Asbt; Slc10a2), effluxed into portal blood by the 
Organic solute transporter heterodimer (Ostα/β), and then taken up in the 
hepatocyte by the Sodium-dependent taurocholate co-transporting polypeptide 
(Ntcp; Slc10a1) [118].  Expression of Ntcp, Bsep and Asbt  are all increased in 
lactation [82, 84],  as is the size of the bile acid pool [10].  We recently 
demonstrated that expression and activity of Cyp7a1, the enzyme catalyzing the 
rate limiting step in the conversion of cholesterol to bile acids, is increased at 
mid-lactation (day 10 – 14 postpartum) [10].  Further, this increase occurs at 16 h 
(10 h of light on a 12 h/light dark cycle; 4 PM) and represents a shift in the diurnal 
rhythm of Cyp7a1 expression, which is normally maximal in the dark cycle (i.e., 
22 h).  Increased expression of Cyp7a1 is apparently due to decreased 
expression of Fibroblast Growth Factor 15 (Fgf15) in the ileum, resulting in 
decreased FGF15 signaling via Fibroblast Growth Factor Receptor 4 (Fgfr4) and 
Erk1/2 in liver and decreased repression of Cyp7a1 transcription [119].   
 
In order to identify further changes in expression of genes important in the 
regulation of bile acid and cholesterol synthesis, as well as other genes important 
in meeting nutritional demands and physiological changes of the lactating rat, we 
carried out a microarray experiment in the liver and small intestine of the lactating 
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dam at 16 h on days 10 -11 postpartum and compared these to gene expression 
in female virgin control rats. 
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RESULTS  
Detection of differentially expressed genes 
 
A repeated measures mixed model ANOVA was used to test for effects of tissue 
and lactation, as described in Methods.  A statistically significant difference was 
determined to exist when the physiologic state effect (comparison between all 
control samples against all lactating samples) yielded a p< 0.05 and the effect of 
lactation within a given tissue (physiologic state simple effect) yielded a p< 0.01.  
Analyzed data are available in Additional File 3.1: 
Statistical_Analysis_and_Statistical_Pattern_Matching_Results.txt.  These p-
values were used as cutoffs for differentially expressed genes and led to the 
proportions of false positives that are listed in the section titled “Approximation of 
false discoveries” below.   
 
A number (1,114) of genes demonstrated an interaction at p< 0.01 and 556 
genes passed a Benjamini-Hochberg false discovery rate correction at FDR=0.05 
(Additional File 3.2: Benjamini_Hochberg_False_Discovery_Rates.txt).  These 
genes represent those that displayed a different response to lactation in one 
tissue with respect to the other tissues.  However, it should be noted that this list 
was not a useful cutoff, as genes that responded uniformly to lactation across all 
tissues would be ignored.  Also, five genes that passed the Benjamini-Hochberg 
correction did not show any significant changes at p<0.01 when the effect of 
lactation was tested within each tissue.  Since the primary purpose of this study 
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was to characterize the influence of lactation on gene expression on these 
tissues, the interaction term was not used.  The tissue effect p-values indicated 
that many (70% at p<0.01) genes were differentially expressed across tissues, 
due to the large difference in cell types between the liver and the small intestine.  
Therefore, we chose the cutoffs of a physiologic state main effect at p<0.05 and 
the effect of lactation within at least one tissue at p<0.01, as described in the 
Methods.   
 
 Although not as many genes were detected as significantly differentially 
expressed compared to the overall tissue effect, the overall physiologic state 
effect and the pairwise comparisons (effect of lactation in each tissue) showed a 
high number of low p-values, indicating that the tissues in question responded to 
lactation at the level of mRNA.  Several genes were downregulated in the 
duodenum only (34 genes), with 23 genes showing over a 50% decrease.  
Members of this group are listed as pattern “-100” in Additional File 3.1.   
Histograms displaying the distribution of p-values are in Additional File 3.3: 
Histograms_of_p_values.ppt , and volcano plots displaying each tissue’s 
response to lactation are in Additional File 3.4: Volcano_plots.pdf.   
 
Approximation of false discoveries 
 
The proportion of false positives is an approximation of the ratio of false positives 
in the list of genes listed as differentially expressed.  An estimate of the number 
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of false positives was calculated for all tissues using genes where p<0.05 for an 
overall physiologic state effect, and for each tissue using genes with an effect of 
lactation within each tissue (here defined as a simple effect) of p<0.01.  Thus, the 
proportion of false positives (PFP) was calculated as (p-value cutoff X number of 
genes tested)/number of genes detected below the p-value cutoff.  The PFP as 
defined by Fernando et al [120], is E(V)/E(R) where E(V) is the expected number 
of false rejections of the null hypothesis and E(R) is the expected number of 
rejections of the null hypothesis.  Here we utilized the actual number of rejections 
of the null hypothesis as the expected value.  Of all of the genes on the chip, 
14,129 genes were found to be annotated and expressed in at least one tissue/ 
physiologic-state combination and were used for statistical tests.  Of those 
genes, 1,924 had an overall physiologic state p-value of less than 0.05, yielding a 
PFP of 0.37; at an overall physiologic state p<0.01, 690 genes were detected, 
yielding a PFP of 0.20.  PFPs for the individual tissues at a cutoff of p<0.01 for 
the pairwise comparisons (simple effects) were 0.17 for the liver, 0.28 for the 
duodenum, 0.22 for the jejunum, and 0.18 for the ileum.  The PFPs for the 
individual tissue calculations examined only the genes detected at a simple effect 
p<0.01, and not at the combined overall physiologic state cutoff of p < 0.05 
together with the within-tissue cutoff of p< 0.01, as some genes passed the p< 
0.01 cutoff within a given tissue, but did not pass the initial overall physiologic 
state effect cutoff of p< 0.05.  The rationale for not utilizing the overall physiologic 
state effect together with the within tissue physiologic state effect in the 
calculation was that these multiple tests were utilized for the same gene.  
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Consequently, the list of genes reported at both p<0.05 for the physiologic state 
and p<0.01 for the comparison within a tissue was a subset of the list of genes 
that only show a p<0.01 within a tissue.  The physiologic state cutoff of p< 0.05 
was chosen to protect against repeated testing for each tissue; this value was 
also chosen because changes that only occurred within one tissue would be 
difficult to detect if the overall physiologic state cutoff was made at p< 0.01.  
Approximations of the proportion of false positives in this range (0.17 – 0.28) 
have been reported previously [121].   
 
RT-PCR Validation of Microarray Data 
 
Results from RT-PCR analyses agreed with the trends detected in the microarray 
analyses (Table 3.1).  In some cases, significance calls differed, but the 
directionality of the changes observed was consistent with the microarray data.  
Possible causes for disagreement included the fact that different methods of 
normalization were used between RT-PCR and the microarray.     
 
Patterns  
 
Patterns were identified using statistical pattern matching [122, 123] by assigning 
each gene as significantly “up”, “down”, or “no change” detected in each tissue.  
The results of the statistical pattern matching showed that fifteen genes were 
upregulated in all four tissues, while thirty-one genes were downregulated in all 
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four tissues.  Seventy-two genes were upregulated in liver only, and another 
ninety-nine genes were downregulated in liver only.  Results from analyses of 
each pattern using DAVID [104] are shown in additional file 3.5: 
DAVID_output_file.txt. 
 
Of the fifteen genes upregulated in every tissue (Table 3.2), seven were 
identified by DAVID as being involved in the Biosynthesis of Sterols pathway, 
where p=4.59X10-13
88
, using the list of “Up in All Tissues” for the DAVID analysis.  
One gene, transmembrane protein 97 (Tmem97), has been identified as being 
regulated by the Srebp proteins [ , 124], and was recently suggested to aid in 
Low density lipoprotein receptor (Ldlr) function [124].  Amongst genes not 
associated with biosynthesis of sterols, RNA (guanine 9) methyltransferase 
domain containing 2 (Rg9mtd2), is the homolog for a tRNA methyl transferase 
that occurs in yeast [125]. Slc39a4_predicted was upregulated in all tissues, 
consistent with increased zinc absorption during lactation, and is discussed 
further below.   
 
Thirty-one genes were identified as downregulated in all tissues (Additional File 
3.6: Genes_with_decreased_mrna_all_tissues.pdf).  According to the over-
representation analysis in DAVID, the KEGG T cell receptor pathway was over-
represented in this group (p=0.004) [105, 126] (Additional File 3.5), although only 
three genes appeared in this list.  This pathway did not pass any of the multiple 
testing procedures available in DAVID, but is consistent with the IPA results, 
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which flagged “T-cell signaling and differentiation” to be downregulated in the 
jejunum and ileum (Figure 3.1). 
 
Genes downregulated only in the duodenum were also investigated using 
DAVID, as several genes revealed a strong downregulation in this tissue 
(Additional File 3.5).  Many of these genes have been identified as being 
expressed in the pancreas, i.e., eight of the 34 genes in this group matched the 
Sp_PIR keyword “pancreas” (p=5.00X10-15
 
).  The function of these genes in the 
duodenum and the reason for their poor expression in lactation is not known.   
The list of genes upregulated in all parts of the small intestine was not 
significantly enriched by any KEGG pathways in DAVID.  The term Lipid 
Biosynthetic Process was overrepresented (p=0.001), although this term did not 
pass any multiple testing correction available in DAVID. 
 
“The Fibronectin Type III fold” Interpro entry was flagged as overrepresented in 
the list of genes downregulated in the small intestine, but not in liver. [The genes 
associated with the Fibronectin Type II fold entry were Interleukin receptor 22, 
alpha 2 (Il22ra2), Immunoglobulin superfamily 9 (Igsf9), Insulin receptor (Insr), 
Rims binding protein 2 (Rimbp2), and Protein tyrosine phosphate receptor type g 
(Ptprg)].  However, the relevance of the downregulation of these genes in 
lactation is not known.    
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Categories overexpressed in the list of genes upregulated in the liver only 
included the gene ontologies for “response to nutrient levels” and “cholesterol 
metabolic process”.  The list of genes downregulated in the liver showed the 
gene ontology associated with positive regulation of programmed cell death and 
may partially explain the increased liver size during lactation [8, 127]. 
 
Bile acid biosynthesis 
Expression of Cyp7a1, the enzyme catalyzing the rate limiting step of bile acid 
biosynthesis, was detected to be increased (p=0.0002) in the liver with a 1.76-
fold change.  Few other changes were detected in the bile acid biosynthetic 
pathway.  Expression of Cyp46a1, Ch25h, Cyp27a1, Cyp39a1, Cyp7b1, Cyp8b1, 
Akr1d1, Slc27a5, Acox2, Scp2, and Baat [128] did not show a significant change 
in the liver, suggesting that the increase in bile acid biosynthesis observed was 
triggered by the increase in Cyp7a1 mRNA [10].  These data are consistent with 
our earlier detailed characterization of mRNA and protein expression of Cyp7a1, 
Cyp27a1 and Cyp8b1 in lactation [10].   
 
Ingenuity Pathways Analysis  
 
The lists of differentially expressed genes for each tissue, based on the overall 
physiologic state effect p-value and the respective simple effects were examined 
by IPA.  The three overrepresented pathways with the lowest p-values in each 
tissue are shown in Table 3.3, and selected pathways are discussed below. 
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Cholesterol synthesis and metabolism 
 
 “Biosynthesis of steroids” had the lowest p-value among IPA’s “Canonical 
Pathways” in three of the four tissues, with the jejunum being the exception.  At 
the designated cutoff (p< 0.01), the jejunum showed a much more modest 
change in the “biosynthesis of steroids” pathway (p = 0.011 for 
overrepresentation in jejunum; p<1X10-6 
87
in all other tissues).  Detailed 
visualization of the pathway revealed that the upregulated sections of the 
“biosynthesis of steroids” pathway corresponded with cholesterol synthesis 
(Additional Files 3.7-3.10: Biosynthesis_of_sterols_in_liver.jpg, 
Biosynthesis_of_sterols_in_duodenum.jpg, 
Biosynthesis_of_sterols_in_jejunum.jpg, and 
Biosynthesis_of_sterols_in_ileum.jpg).  Since cholesterol synthesis is regulated 
by Srebp proteins, Srebp-regulated genes were investigated further.  To 
determine if an exceptionally large number of Srebp-regulated genes were in the 
list of differentially expressed genes, a list of genes shown to be regulated by 
Srebp by detection through microarray analysis in Srebp-overexpressing and 
Scap knockout mice was used for a right-tailed Fisher’s Exact test [ ] using an 
online calculator (www.Langsrud.com/Fisher.htm).  Here, a p-value of <0.01 in 
the tissue being tested was defined as a positive test for the purpose of 
determining whether a given gene was differentially expressed.  
 
46 
 
Of the 33 genes reported to be regulated by nuclear Srebp proteins [87], 29 were 
present in the data set.  A Fisher’s exact test p-value of p<0.001 was calculated 
for each tissue, with the jejunum (p=0.00029) having the fewest genes displaying 
a significant change (eight genes).  Additional File 3.11: 
Genes_Regulated_by_Srebp_proteins.pdf lists members of the cholesterol 
biosynthetic pathway and other genes that have been shown to be differentially 
expressed in Srebp-overexpressing mice and Scap knockout mice [87] and 
indicates the p-values for each tissue and the ratio of the background-corrected, 
normalized, untransformed intensities (lactation intensity/control intensity).  As 
shown in Figure 3.2, Hmgcr mRNA expression was increased in three of the four 
tissues, with no change detected in the jejunum (p = 0.14).  mRNA expression for 
the genes (Srebf1, Srebf2) encoding the Srebp proteins were not differentially 
expressed, although a tendency for a change was detected in the jejunum, where 
the simple effect comparison p-value for Srebf1 was 0.0006, and the overall 
physiologic state effect p value was 0.054.  Expression of Insig1 mRNA, which is 
regulated by Srebp activity, showed a significant increase in each part of the 
small intestine.  In contrast, an increase in Scap mRNA occurred in the liver only 
(p = 2.18E-7).  Ldlr mRNA was upregulated in the duodenum and jejunum, and 
Tmem97 mRNA, an Srebp target [124], was upregulated in all tissues; both Ldlr 
and Tmem97 proteins aid in LDL uptake by cells [124].   
 
Cholesterol uptake 
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The only gene known to mediate cholesterol uptake in the gut, Npc1l1 [129], is 
not contained in the extended dataset for the Affymetrix Rat Exon 1.0ST.  
Investigation of the “full” and “all” datasets indicated that no probeset on the chip 
was annotated as Npc1l1.  Therefore, expression of Npc1l1 was investigated by 
RT-PCR (Table 3.1).   No significant changes were detected in Npc1l1 
expression in any tissue.   Abcg5 and Abcg8, which function as a heterodimer to 
efflux cholesterol from the enterocyte into the gut lumen and from the hepatocyte 
into bile [130], showed decreased expression in the liver (Abcg5 p=2.9X10-7; 
Abcg8 p=3.6X10-6
 
) and in the ileum (Abcg5 p=0.0062; Abcg8 p=0.0048) (Table 
3.4).  
Transporters 
 
The ATP binding cassette (ABC) transporters that showed a significant change in 
at least one tissue were also investigated (Table 3.4).  The ABC transporters are 
a superfamily of membrane transporters with diverse substrates that in 
eukaryotes mediate the ATP-dependent efflux of endogenous substrates, 
including bile acids and cholesterol, as well as of xenobiotics, including many 
drugs.  The ABC transporter Abcb1a (Mdr1a) was downregulated in every tissue.  
This protein effluxes xenobiotics across the apical domain of the hepatocyte into 
bile, and in the enterocyte and plays an important role in limiting absorption of 
orally administered substrates [131].  Two members of the Abcc (Mrp) subfamily, 
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Abcc5 and Abcc6, were downregulated in the ileum, while Abcg2 expression was 
increased in the duodenum. 
 
Solute carrier proteins (Slcs) are a superfamily of proteins that transport many 
different molecules, including amino acids and ions (www.bioparadigms.org).  All 
Slcs on the chip were investigated and those with a detected significant change 
in lactation in any tissue are shown in Additional File 3.12: Slcs.pdf.  For each 
tissue, nearly 20% of the Slcs showed a change at an overall physiologic state 
effect of p <0.05, and approximately 5% were declared significant after applying 
a p<0.01 cutoff within a tissue (simple effect) 
 
Slc39a4 is a transporter mediating the uptake of zinc into the intestine [132].  
Slc39a4_predicted was one of fifteen genes to be significantly upregulated in 
every tissue (p<1X10-5
 
) (Additional File 3.1).  Fold changes for Slc39a4 predicted 
based on untransformed intensity values ranged from 1.65 in the jejunum to 2.81 
in the liver (Table 3.1). 
Thyroid signaling 
 
A Fisher’s exact test using IPA detected significant overrepresentation in the 
TR/RXR pathway in every tissue.  (Additional Files 3.13-3.16: 
Liver_canonical_pathways.txt, Duodenum_canonical_pathways.txt., 
Jejunum_canonical_pathways.txt., and Ileum_canonical_pathways.txt).  Thyroid 
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hormone receptor α (TRA, Thra) and thyroid hormone receptor β (TRB, Thrb) 
were both downregulated in the ileum and jejunum.  A decrease was also seen in 
the liver, but the change was not significant (p = 0.07 for TRA; p = 0.018 for 
TRB).    Surprisingly few of the downstream genes of TR/RXR were 
downregulated in the IPA depiction of this pathway.  In some cases, overlap 
occurred with Srebp signaling, and increased signaling from Srebp appeared to 
have overridden decreased thyroid signaling.  This seems to have occurred with 
Acetyl-CoA Carboxylase alpha (Acaca) in the liver and Ldlr in both the duodenum 
and jejunum [87].  One TRB/RXR regulated gene [24], Kruppel like factor 9 
(Klf9), which is a transcription factor associated with intestinal proliferation, was 
downregulated in every tissue (Additional Files 3.17-3.20: 
Liver_thyroid_pathway.jpg, Duodenum_thyroid_pathway.jpg, 
Jejunum_thyroid_pathway.jpg, and Ileum_thyroid_pathway.jpg).  Klf9 knockout 
mice have shorter intestinal villi, although Klf9 is typically considered a 
transcriptional repressor and can also negatively regulate growth [33].   
 
Decreased mRNA from T-Cell receptor signaling and related pathways 
 
mRNA of genes coding for the components of T-Cell receptor signaling pathway 
in IPA showed significant downregulation in the jejunum and ileum (p = 1.68X10-7 
and p = 4.7X10-4, respectively) (Figure 3.1).  A similar pathway, the “CD28 
receptor signaling in T helper cells” pathway was also downregulated in the 
jejunum, but substantial overlap between the two pathways suggested 
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observation of the same events.  These pathways are upstream of IL-2 
production [133], however, the microarray detected no change in IL-2 mRNA in 
any tissue.  
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Discussion  
 
Cholesterol Biosynthesis 
 
IPA and DAVID both flagged “Biosynthesis of Steroids” to be overrepresented in 
the list of differentially expressed genes in lactation in three of the four tissues 
(the jejunum displayed a p-value near the cutoff), and the list of genes 
upregulated in all tissues during lactation, respectively (Additional Files 3.7-3.10).  
Visualization of this pathway revealed that the genes identified were components 
of the cholesterol biosynthetic pathway.  Statistical pattern matching as well as 
results from overrepresentation analyses in both DAVID and IPA indicated that 
expression of cholesterol biosynthetic genes was induced in all tissues 
examined, although to a lesser extent in the jejunum (p=0.011; Benjamini-
Hochberg corrected p=0.048, values calculated by IPA).   Cholesterol and lipid 
biosynthetic genes are known to be regulated by transcription factors known as 
the Srebp proteins.  Three Srebp proteins are encoded by two genes, Srebf1 and 
Srebf2.  Srebf1 codes for Srebp-1a and Srebp-1c, while Srebf2 codes for Srebp-
2.  The Srebp proteins differ in their control of fatty acid synthesis and cholesterol 
biosynthesis [88, 91, 134].  Srebp-2 is associated with cholesterol biosynthesis, 
while the Srebp1 proteins are associated with fatty acid synthesis [88], although 
there appears to be overlap in the genes that are responsive to these 
transcription factors [87].  Srebp-1c is sensitive at the transcriptional level to LXR 
signaling [91, 135, 136], while all three share a mechanism for becoming an 
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active transcription factor [91].  Under conditions of sufficient cholesterol 
concentrations, the protein product of Insulin stimulated gene (Insig) binds to 
Srebf Chaperone (Scap) to retain an Insig/Scap/Srebp complex in the 
endoplasmic reticulum [91, 137].   In the absence of oxysterols and cholesterol, 
Insig is degraded and Scap is released from the endoplasmic reticulum; Scap 
then escorts the bound Srebp to the Golgi, where the N-terminus of the Srebp is 
cleaved from the full protein to generate the active form that functions as a 
transcription factor [134]. As indicated above, cholesterol synthesis is increased 
during lactation in both the liver and the small intestine [2, 3] and Srebp target 
genes have also been shown to be upregulated in mammary tissue in lactating 
dams [89].  In a review article, Shimano lists in a table (Shimano, Table 1) a 
series of genes with known SRE elements and their promoter sequences [138].  
Of the genes in this table, low density lipoprotein receptor (Ldlr), HMG CoA 
synthase1 (Hmgcs1), HMG CoA reductase (Hmgcr), farnesyl diphosphate 
farnesyl transferase 1 (Fdft1), Cytochrome P450 family 51 (Cyp51), Acetyl CoA 
carboxylase (Acc), Stearoyl CoA desaturase 2 (Scd2), and malic enzyme 1 
(ME1) are all upregulated in at least one tissue.    
 
The observation that Srebp-regulated genes were upregulated is consistent with 
early data showing an overall increased cholesterol biosynthesis in lactation [9].  
We currently do not know which Srebp isoforms are involved in the changes 
seen in lactation, as Srebp-1c, Srebp-1a and Srebp-2, are all able to regulate 
expression of cholesterol synthetic genes.  However, Srebp-2 plays a stronger 
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role in regulating these genes [88].  The only potential change detected in the 
mRNA for a Srebf gene was Srebf1, the gene associated with Srebp-1a and 
Srebp-1c, which showed increased mRNA levels in the jejunum.   
 
In the liver, Scap mRNA showed a significant increase (p = 2.2X10-7
91
).  If this 
change were associated with an increase in Scap protein levels, then a probable 
mechanism for the increase in Srebp target genes in the liver would be increased 
transport of Srebp proteins to the Golgi, and their subsequent delivery to the 
nucleus [ ].  Insig1 mRNA also showed a significant increase in all parts of the 
small intestine, but not in the liver.  Insig1 functions to retain Srebp in the 
endoplasmic reticulum.  Thus, increased expression of Scap in liver and 
increased expression of Insig1 in intestine provide a likely mechanism for the 
greater increase in cholesterol synthesis in liver vs. intestine observed by 
Feingold et al [9].   
  
A number of factors contribute to the increased need for cholesterol in the 
lactating dam.  The dam requires significant cholesterol for the increased 
synthesis of bile acids; 50% of cholesterol catabolized in the liver from 
nonlactating rats is used for bile acid synthesis [139].  Since the size of the bile 
acid pool increases 2-3-fold at 10 -14 d of lactation [10], greater than 50% of 
cholesterol is likely catabolized to bile acids in lactation.  The proportion of 
dietary cholesterol vs. endogenously synthesized cholesterol that is catabolized 
to bile acids in nonlactating vs. lactating rats is not known.  Most importantly, 
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cholesterol is an essential component of milk that supports membrane synthesis 
and neurodevelopment in the pups [140].  About 16 mg per day of cholesterol is 
secreted into the milk in rats [141]; between 32 and 40% of this cholesterol is 
synthesized in the mammary gland, while 11% is absorbed from the diet [86].  
Thus, cholesterol synthesized in the liver makes up about 50% of cholesterol 
secreted in milk [86].   
 
In addition to detecting a change in cholesterol synthesis, a possible mechanism 
for improved net cholesterol uptake was found.  Abcg5 and Abcg8 show 
decreased levels of mRNA expression in the liver and ileum.  A decrease in the 
concentration of active Abcg5/Abcg8 heterodimer in the intestine would be 
expected to yield an increase in net cholesterol uptake through decreased efflux 
from the enterocyte into the gut lumen, while decreased hepatic expression 
would minimize cholesterol secretion into bile [93].  The decreased expression of 
Abcg5/g8 mRNA in the liver, together with increased expression of cholesterol 
synthetic genes, likely serve to enhance conservation of cholesterol to allow for 
sufficient transfer of cholesterol into the milk and for synthesis of bile acids.  
Increased synthesis of bile acids would in turn serve to increase cholesterol 
absorption [90].   Taken together, these data suggest a concerted mechanism for 
enhancing net cholesterol absorption and minimizing its elimination to ensure 
sufficient cholesterol for incorporation into milk and bile acid synthesis, both 
important factors in maintaining the health of both the dam and pups.   
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Zinc 
 
Statistical pattern matching found that Slc39a4_predicted mRNA was increased 
(1.65 to 2.81 fold) in all tissues.  Slc39a4 is a major zinc transporter associated 
with zinc import into the enterocyte [132], and zinc absorption is up-regulated in 
lactation [73-76].  Taken together, these data imply that the increased expression 
of Slc39a4 mediates the increased zinc absorption that occurs in lactation.  Zinc 
is an essential nutrient shown to be important in bone development [75], to play a 
role in stimulating the insulin pathway [142] and in controlling T-Cell activity [143].  
Zinc requirements are increased during lactation relative to pregnancy, and 
therefore net zinc uptake needs to be increased to maintain zinc homeostasis 
during lactation in humans, particularly during early lactation [144].  Interestingly, 
alpha-2-macroglobulin (A2m) showed a substantial increase in mRNA expression 
(~15-fold) in the liver. Zinc can directly regulate A2m’s ability to sequester 
cytokines [143, 145, 146] by enhancing formation of a form of A2m that contains 
free sulfhydryl groups, which serve as binding sites for the cytokines [146]. 
 
Downregulation of mRNA from the T-Cell signaling pathway 
 
Both the jejunum and ileum showed strong downregulation at the mRNA level of 
the proteins composing the T-Cell signaling pathway in IPA.  These changes may 
reflect a decrease in the number of actual T-Cells in the small intestine of 
lactating rats.   
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Xenobiotic Transporters 
 
Table 3.4 displays significantly different changes in mRNA concentration for the 
ABC transporters.  Included in this list of genes are Abcb1a (Mdr1a), Abcc5, 
Abcc6, and Abcg2.  Abcb1a showed decreased expression in all tissues in the 
microarray and this was successfully validated for the jejunum and ileum by RT-
PCR.  Abcc5 and Abcc6 also showed decreased mRNA expression in the ileum.  
Decreased expression of these efflux transporters would in general lead to an 
increased net absorption of their substrates.  In contrast, Abcg2 showed 
increased expression in the duodenum, which would decrease absorption of 
substrates.  Sample substrates for these proteins include drugs such as digoxin 
and cyclosporine A  (Abcb1a, [147]), cGMP (Abcc5 [148]), the glutathione 
conjugate leukotriene C4 149 (Abcc6 [ ] [150]), and 2-amino-1-methyl-6-
phenylimidazo[4,5-b] pyridine, a dietary carcinogen (Abcg2 [151]).  Further work 
is needed to understand the impact of these specific changes within the context 
of lactation on the lactating dam and her pups.     
 
TR/RXR Pathway 
  
IPA found members of the TR/RXR pathway to be overrepresented in the list of 
differentially expressed genes in each tissue. In both the ileum and jejunum, both 
TRA and TRB showed down-regulation.  Although lactating rats are hypothyroid 
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[19] and expressed lower levels of mRNA for thyroid receptor in these tissues, 
not all thyroid responsive genes were down-regulated, including Apoa5, Eno1, 
and Glut1, which showed no change in any tissue.  A more detailed picture of the 
thyroid receptor pathway can be found in Additional Files 3.17-3.20. Serum 
thyroid hormone levels and early steps in the pathway are likely downregulated 
as an attempt to conserve energy [19, 152].  Fisher’s exact test determines its p-
values based on the counts of the number of genes in the list of differentially 
expressed genes and compares these to the total number of genes in the 
pathway relative to the total number of genes in the microarray.  Therefore, 
pathways that overlap are likely to be detected as overrepresented if the 
overlapping genes are in the list of differentially expressed genes.  Because 
some Srebp regulated genes are considered to be part of the TR/RXR pathway, 
the p-values for overrepresentation may be low, even if thyroid signaling overall 
was unchanged.  However, changes in the mRNA levels of the thyroid receptors 
argue against this, since these receptors have not been shown to be Srebp 
targets. 
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Conclusions  
 
The present studies have shown an increase in the mRNA of enzymes involved 
in the cholesterol biosynthesis pathway, implying that the sterol regulatory 
element binding proteins are more active in the liver and small intestine in 
lactating vs nonlactating rats.  The data are consistent with a coordinated 
response to the overall increased energy demands of lactation and the specific 
needs of the pups for cholesterol so that there is adequate cholesterol for 
incorporation into milk and increased synthesis of bile acids; the latter in turn 
function to increase the intestinal absorption of cholesterol and lipids.   We also 
demonstrated a marked increase in the expression of a key transporter important 
in the uptake of the essential element, zinc.  Finally, we detected decreased 
mRNA from genes associated with T-cell signaling in the jejunum and ileum.   
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Methods 
 
Animals 
 
Sixteen Sprague-Dawley rats that were lactating for 10-11 days and sixteen age-
matched virgin controls were obtained from Harlan (Indianapolis, IN) and 
maintained on a 12 h light/dark cycle (6 AM lights on/6 PM lights off).  Rats had 
free access to Teklad Global Diet 2018 (Harlan Laboratories, Cincinnati, OH) and 
water. In order to minimize the variance in energy demands on the lactating dam, 
pups were removed from large litters within 24 hours of birth so that all litters 
contained 8-11 pups.  All animals were sacrificed at 16 h (10 h of light on a 12 h 
light/dark cycle; 4 PM), and the liver, duodenum, jejunum, and ileum were 
removed for total RNA extraction from each tissue.  The first 5 cm of the small 
intestine following the pyloric sphincter was taken as the duodenum, while the 10 
cm following the ligament of Trietz was discarded and the next 20 cm used as 
the jejunum.  The 20 cm segment preceding the cecal valve was taken as ileum.  
The mucosal layer was removed by scraping at 4°C, and used for isolation of 
RNA from intestinal segments.  RNA was extracted from homogenized tissue 
using Trizol (Invitrogen, Carlsbad, CA), and purified using RNeasy Mini Kit 
DNAse and columns (Qiagen, Valencia, CA).  The integrity of all RNA samples 
was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA).  Animal protocols were conducted in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals and 
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were approved by the Institutional Animal Care and Use Committee of the 
University of Kentucky.   
 
Each rat was assigned to one of four pools within the respective physiologic state 
(four control pools and four lactating pools).  Pooled RNA samples, consisting of 
the RNA from the four rats within the same group, were created for each tissue, 
with individual rats composing the pools consistent across tissues. Each pooled 
sample (RNA from one tissue from one set of four rats) was loaded onto a 
separate chip.  This resulted in the use of 32 chips (4 tissues X 2 “physiologic 
states” X 4 pools).  Samples were prepared and processed according to the 
manufacturer’s instructions by the University of Kentucky Microarray Core Facility 
(Lexington, KY).   
 
Selection of Genes on Which to Perform Statistical Analysis 
 
Affymetrix Expression Console software was used to perform the Robust 
Multichip Average (RMA) [99, 100] algorithm, which background corrected, 
quantile normalized, and log2-transformed gene level summaries of the Extended 
dataset.  Affymetrix has divided the chip into various datasets, which represent 
different confidence levels with respect to the complementarities between the 
probe and the sense strand of the gene sequences.  The Extended dataset 
consists of the Core dataset, which is made up of Refseq entries and full length 
mRNAs, as well as additional multiple annotations based on cDNA libraries.  
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Although the Core dataset probes are the best annotated, the rat genome is not 
as well annotated as the human and mouse genomes, with many of the genes in 
the rat Extended dataset identified based on their similarity to human or mouse 
genes. Use of the Extended dataset allowed a more thorough analysis of the 
genome.  The summarized values are an average taken across all exons.   
 
The exon level Affymetrix DABG (Detection Above Background) values and the 
Affymetrix annotation file (version raex_1_0-st-v1.na27.rn4) were used to filter 
the data [110].  Exon level data was opened in Expression Console and the RMA 
algorithm and log2
110
 transformations were performed.  An exon was considered 
present if it had a DABG p < 0.01, indicating that the exon in question had an 
intensity greater than 99% of the background probes with the same GC content 
[ ].  A gene was considered for analysis if at least one exon was detected on 
at least two chips within the same tissue and the same physiologic state, e.g., 
presence on two control liver chips.  Genes were also removed if the Affymetrix 
annotation file contained a “---“ or a blank for the “mRNA description” entry 
(Annotation file: raex_1_0-st-v1.na27.rn4).  Of the 19,434 genes in the Extended 
dataset, 14,129 were utilized for statistical tests based on these criteria.    
 
Statistical Analysis 
 
Since all four tissues were taken from each rat, a repeated measures mixed 
model ANOVA was used to determine if changes in expression were statistically 
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significant for each gene [153].  JMP genomics version 4.1 (SAS Institute Inc, 
Cary, NC, 2011) was used to perform the ANOVA using compound symmetry to 
model the covariance matrices.  Tissue, physiologic state, and the 
tissue*physiologic state interaction were treated as fixed effects, while “pool”, a 
variable describing the combination of four individual rats to create a sample, 
was treated as a random subject variable.   
 
A common method for addressing multiple testing issues involved in the analysis 
of microarrays is the Benjamini-Hochberg false discovery rate (FDR) correction.    
Several possibilities existed for attempting to address the issue of multiple 
testing.  First, the physiologic state p-value could be adjusted to a fixed FDR.  
Alternatively, the individual unadjusted p-values for the simple effects could be 
set to a given value and an approximation of the number of false positives within 
a group could then be calculated.  We chose the latter approach, set p<0.01 as a 
cutoff and calculated the proportion of false positives (PFPs) for the simple 
effects that represented the pairwise comparisons within a tissue.  We chose this 
method to balance the risk of false positives with the risk of false negatives.  
False negatives in the list of differentially expressed genes could interfere with 
downstream pathway analyses. 
 
The overall physiologic state effect of p< 0.05 also served as an additional cutoff 
to reduce the total number of statistical tests performed.  Selection of an overall 
physiologic state p-value of p< 0.01 was problematic, as genes that displayed 
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differential expression in only one tissue might not be noticed due to the lack of 
change in the remaining tissues. In summary, genes were considered 
differentially expressed between control and lactation within a tissue if a 
significant physiologic state effect was observed at p<0.05 and a simple effect for 
the pairwise comparison within a tissue was p< 0.01.   
 
.CEL files and .CHP files describing the data are available through GEO under 
GSE19175 and analyzed data is available in Additional File 3.1. 
 
Detection of Biological Trends 
 
Ingenuity Pathways (IPA) (www.ingenuity.com) was used to screen the results 
for biological trends.  Differentially expressed genes were determined as 
described in the “Statistical Analysis” section above.  The Rat Exon 1.0 ST chip 
was used as a background list.   
 
A right tailed Fisher’s Exact test was used to screen the IPA database and detect 
categories that were overrepresented based on genes detected to have a 
significant difference in expression.  Available in IPA is the Benjamini-Hochberg 
correction, which attempts to control the number of false positives.  This 
calculation is dependent on the size of the database.   We chose not to use the 
Benjamini-Hochberg correction, but chose to fix the significance threshold at 
p<0.01 for any given test.  A p< 0.01 for the Fisher’s Exact test indicated that 
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more genes in the list of differentially expressed genes appeared in a pathway 
than would be expected by chance if the same number of differentially expressed 
genes were to be selected randomly from all genes on the chip.  Both these p-
values and the Benjamini-Hochberg p-values are provided in Table 3.3.   
 
The lists generated by statistical pattern matching were analyzed by DAVID [104, 
105] with the 14,129 genes used for statistical analyses as the background list.   
The lists screened for overrepresentation were the Canonical Pathways category 
in IPA and several databases in DAVID (see below). For the Srebp transcription 
factors, a report of the differential gene expression in mice overexpressing 
isoforms of Srebp and in Scap knockout mice was used to create an additional 
list of genes known to be regulated by the Srebp proteins [87]. Out of the 33 
genes listed as regulated by nuclear Srebp-1a and Srebp2, 29 were identified as 
being on the chip at the level of the Extended dataset and were used to perform 
a right tailed Fisher’s Exact test. 
 
We used IPA’s Canonical Pathways database for all changes detected within a 
tissue, while we used all Gene Ontology terms, COG ontology, Sp_PIR Keyword 
[154, 155], UP_SEQ_Feature [154, 155], Interpro [156], PIR_Superfamily [157], 
SMART [158, 159], and KEGG [126, 160, 161] as databases in DAVID for testing 
each pattern detected by statistical pattern matching.   
 
Statistical Pattern Matching 
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In order to assign changes of RNA expression into biologically meaningful 
groups, a method of statistical pattern matching was used analogous to the one 
used by Arzuaga et al [122] and Hulshizer and Blalock [123].  mRNA from any 
given gene could increase expression, decrease expression, or show no change 
in expression in samples from lactating animals compared to controls in each 
tissue.  The method for pattern matching is described in a step by step manner 
as follows.   Only genes that tested positive for differential expression were used 
for pattern matching.  These genes were assigned an additional significance call 
at p<0.05 for each simple effect within a tissue.  This was done to protect against 
incorrectly assigning a gene that systematically had low p-values as differentially 
expressed in only one tissue.  For example, if a gene was downregulated with p 
values of less than 0.01 in the liver, duodenum, and jejunum, and a p of 0.03 in 
the ileum, the gene was assigned as differentially expressed in all tissues rather 
than in three of the four tissues.  Although the gene would not have been 
considered differentially expressed for the purposes of evaluating which genes 
were differentially expressed in the ileum, the gene was considered differentially 
expressed for the purposes of assigning a pattern.  This reduced the risk of 
falsely assigning the gene to another pattern in the presence of a false negative.  
The fold-change within a given tissue was then utilized to determine if a gene 
was upregulated or downregulated in each tissue.  For each tissue, three values 
were multiplied to define the change in that tissue.  One value was an integer 
that represented the tissue itself: 1000 for liver, 100 for duodenum, 10 for 
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jejunum, and 1 for ileum.  The second value was a multiplier to define whether or 
not there was a tendency (p<0.05) for the gene to change expression in the given 
tissue, where p<0.05 = 1; p>0.05 = 0).  The third value defined the directionality 
of the change, where upregulation = 1 and downregulation = - 1.  The products of 
these values were used to define the change that occurred within a given tissue.  
For example, a gene upregulated in the liver would have a value of 1000, i.e., 
1000*1*1.  The sum of this value for all tissues was taken to generate a unique 
value for every set of possible changes that could occur across tissues.   For 
example a gene that was upregulated in every tissue except the ileum, where it 
was downregulated would have a value of 1009 (1000 + 100 + 10 - 1).    The 
following groups were defined to be of particular importance and were 
investigated: up in all tissues, down in all tissues, up in all parts of small intestine, 
down in all parts of small intestine, up in liver, down in liver, and down in 
duodenum only.   
 
RT-PCR validation of microarray findings 
 
The same total RNA samples used for the microarray were used for RT-PCR 
validation; RT-PCR was performed as reported previously [162], using the 
geometric average of Ctsb, Tmbim6, and Tmed2 as a normalization constant 
[10].  An aliquot of all cDNA samples was used to generate a standard curve.  
RT-PCR experiments were performed by Dr. Tianyong Zhao in our laboratory.  
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Choosing an appropriate normalization constant was performed using 
methodology similar to that described by Andersen et al [163].  Methods for 
detecting valid internal controls require a list of candidate genes with little or no 
bias, since any bias that exists within the genes detected as valid internal 
controls would be transferred over to the newly calculated normalization factor 
[163].  Genes with high expression (mean log2 
163
intensity from the microarray 
greater than or equal to 10) were sorted by their coefficients of variance.  
Microarray data for the twenty genes with the lowest coefficients of variance were 
input into Normfinder [ ].  The single best gene to use as a control was Ctsb, 
and the best combination of two was found to be Tmbim6 and Tmed2.  We 
performed RT-PCR on these genes and chose to use the geometric mean of the 
three genes as a normalization constant.  The same statistical model that was 
used to analyze the microarray results was used to analyze the normalized RT-
PCR data.    
 
cDNA was synthesized using High-Capacity cDNA Reverse Transcription Kits 
from Applied Biosystems (Foster city, CA) according to the manufacturer’s 
instructions.  Primers and Universal Probes Library (UPL) probes for real time RT 
PCR were designed and ordered from Roche Applied Science (Mannheim, 
Germany) using online software (www.universalprobelibrary.com).  A list of 
primers is provided in Additional File 3.21: RT_PCR_primers.pdf.   The Roche 
Light Cycler 480 was used for performing the RT-PCR.  Briefly, 1 μg of total RNA 
was used for cDNA synthesis, the synthesized cDNA diluted to 500 μL, and 5 μL 
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of diluted cDNA used as template in a 20 μL reaction volume.    For quantification 
analysis of real time RT-PCR data, a standard curve was generated by pooling 
all the cDNA samples to form one cDNA mixture and then diluting this cDNA 
mixture 10-, 100-, 1000- and 10,000-fold so that expression of the gene of 
interest was within the range of the standard curve.    
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Figures 
 
 
 Jejunum 
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 Ileum 
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Figure 3.1.  T-cell signaling in lactating jejunum and ileum 
Downregulation of T-cell signaling in the jejunum (top, p = 1.68X10-7) and ileum 
(bottom, p = 4.7X10-4).  Green shading indicates downregulation of the 
corresponding gene during lactation. 
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Figure 3.2.  Plot of Mean Intensities for Known Cholesterol Biosynthetic 
Enzymes 
The mean untransformed intensities were plotted against tissue/physiologic state 
combination.  C and L indicate the mean of Control and Lactating samples, 
respectively, within each tissue.  Abbreviations for genes are as follows.  Dhcr7: 
7-dehydrocholesterol reductase; Fdft1: farnesyl-diphosphate farnesyltransferase 
1; Sc4mol: sterol-C4-methyl oxidase-like; Idi1: isopentenyl-diphosphate delta 
isomerase 1; Mvd: mevalonate (diphospho) decarboxylase; Hmgcs: 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 1; Hmgcr: HMG Coenzyme A reductase; 
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Lss: lanosterol synthase; Cyp51: cytochrome P450 family 51; Sqle: Squalene 
Epoxidase.  A red line between Control and Lactating symbols for a given gene 
indicates that p>.0.01 for the tissue pairwise comparison within the tissue from 
the mixed models repeated measures ANOVA on the log2
 
 transformed 
intensities; the change was not considered significant for the purposes of 
determining a list of differentially expressed genes.  A black line between C and L 
symbols indicates p< 0.01 as described above.   
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Table 3.1. RT-PCR validation of selected genes from the microarray.   
Gene Symbol 
Transcript 
Cluster ID RL RD RJ RIL 
Tmem97 
7080099 1.52  
(p=0.021) 
1.92 
(p<0.01) 
2.60 
(p<0.01) 
2.03 
(p<0.01) 
1.59 
(p=0.42) 
1.82 
(p<0.01) 
1.73 
(p=0.072) 
2.15 
(p<0.01) 
Npc1l1 
- 1.00 
(p=1.00) 
1.27 
(p=0.49) 
1.22 
(p=0.16) 
0.88 
(p=0.72) 
Abcb1a 
7250393 0.82 
(p=0.91) 
0.63 
(p<0.01) 
0.83 
(p=0.77) 
0.66 
(p<0.01) 
0.72 
(p=0.09) 
0.65 
(p<0.01) 
0.65 
(p<0.01) 
0.70 
(p=0.01) 
Cyp1a1 
7336681 2.98 
(p=0.93) 
2.29 
(p<0.01) 
1.12 
(p=0.64) 
1.23 
(p=0.35) 
2.06 
(p<0.01) 
1.71 
(p=0.02) 
0.78  
(p=0.89) 
0.67 
(p=0.03) 
Cyp3a23/3a1 
7100149 1.83 
(p=0.12) 
1.69 
(p<0.01) 
1.30 
(p=1.00) 
1.23 
(p=0.35) 
BDL 
1.05 
(p=0.50) 
BDL 
1.04 
(p=0.58) 
Fdft1 
7139070 1.36 
(p=0.11) 
1.38 
(p<0.01) 
2.58 
(p=0.22) 
1.98 
(p<0.01) 
1.02 
(p=0.99) 
1.42 
(p<0.01) 
2.41 
(p=0.018) 
1.55 
(p<0.01) 
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Hmgcr 
7202670 2.05 
(p<0.01) 
1.97 
(p<0.01) 
1.52 
(p=0.30) 
1.64 
(p<0.01) 
1.14 
(p=0.80) 
1.17 
(p=0.14) 
1.18 
(p=0.48) 
1.38 
(p<0.01) 
Slc39a4 
7329323 2.71 
(p=0.59) 
2.81 
(p<0.01) 
2.92 
(p<0.01) 
1.89 
(p<0.01) 
2.20 
(p<0.01) 
1.65 
(p<0.01) 
1.99 
(p<0.01) 
1.68 
(p<0.01) 
Sqle 
7317317 
1.80 
(p<0.01) 
1.83 
(p<0.01) 
2.66 
(p=0.03
4) 
2.27 
(p<0.01) 
1.71 
(p=0.50) 
1.72 
(p<0.01) 
1.59 
(p=0.056) 
1.70 
(p<0.01) 
Ugt2b36 
(Ugt2b4) 
7117373 0.85 
(p=0.047) 
0.96 
(p=0.86) 
0.76 
(=0.41) 
0.57 
(p<0.01) 
0.39 
(p=0.21) 
0.37 
(p<0.01) 
0.62 
(p=1.00) 
1.00 
(p=0.97) 
 
Ratios were calculated as Lactating measurement divided by Control 
measurement.  RT-PCR data is reported as the ratio of normalized 
measurements, and microarray data is reported as the ratio of normalized, 
untransformed intensities.  p-Values were calculated using a mixed models 
approach as described in methods.  RL, RD, RJ and RIL are the Ratio of 
Lactation to Control in liver (L), duodenum (D), jejunum (J), and ileum (IL), 
respectively.  BDL, below detection limit.  RT-PCR results are listed as the top 
set of values, and microarray results are listed below. 
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Table 3.2.  Genes that displayed increased mRNA during lactation in all 
tissues 
Transcript 
Cluster ID Gene Name 
RL RD  RJ RIL 
7027017 
Acetyl-Coenzyme A 
acetyltransferase 
1.98 
(p=0.0173) 
2.40 
(p=0.0049) 
1.80 
(p=0.0363) 
2.19 
(p=0.0128) 
7080099 Transmembrane protein 96 
1.92 
(p=0.0001) 
2.03 
(p=2.8e-05) 
1.82 
(p=0.0002) 
2.15 
(p=8.7e-06) 
7113785 
Hydroxysteroid(17-beta) 
dehydrogenase 7 
1.71 
(p=2.1e-06) 
1.54 
(p=4.7e-05) 
1.19 
(p=0.045) 
1.51 
(p=0.0001) 
7132836 
PDZ binding kinase 
predicted* 
1.56 
(p=0.0222) 
1.88 
(p=0.0031) 
1.66 
(p=0.0054) 
1.54 
(p=0.0227) 
7139070 
Farnesyl diphosphate 
farnesyl transferase 
1.38 
(p=0.0009) 
1.98 
(p=4.7e-08) 
1.42 
(p=0.0004) 
1.55 
(p=4.1e-05) 
7144691 
Sterol-C4-methyl oxidase-
like 
1.41 
(p=0.0015) 
2.19 
(p=1.9e-07) 
1.45 
(p=0.0008) 
1.80 
(p=8.2e-06) 
7166170 
Isopentenyl-diphosphate 
delta isomerase 
1.61 
(p=0.0006) 
2.11 
(p=2.8e-06) 
1.33 
(p=0.0226) 
1.91 
(p=2.6e-05) 
7169182 
Kinesin family member 
20a_predicted* 
1.46 
(p=0.0012) 
1.50 
(p=0.0010) 
1.33 
(p=0.0104) 
1.45 
(p=0.0013) 
7186293 
Mevalonate (diphospho) 
decarboxylate 
2.65 
(p=3.8e-05) 
2.15 
(p=0.0004) 
1.49 
(p=0.0316) 
1.73 
(p=0.0042) 
7199743 
RNA (guanine-9-) 
methyltransferase domain 
containing 2 
1.18 
(p=0.009) 
1.42 
(p=3.6e-06) 
1.19 
(p=0.0066) 
1.30 
(p=0.002) 
7250653 CYP51 1.24 2.14 1.50 1.89 
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(p=0.0116) (p=1.8e-09) (p=4.2e-05) (p=6.7e-08) 
7280610 
UDP-Galactose-4-
epimerase 
1.65 
(p=0.0006) 
1.50 
(p=0.0042) 
1.36 
(p=0.0243) 
1.53 
(p=0.0023) 
7291805 
Dehydrodolichyl 
diphosphate synthase 
1.37 
(p=0.0003) 
1.36 
(p=0.0005) 
1.27 
(p=0.0041) 
1.17 
(p=0.0447) 
7317317 Squalene epoxidase 
1.83 
(p=2.4e-05) 
2.27 
(p=5.6e-07) 
1.72 
(p=0.0001) 
1.70 
(p=0002) 
7329323 
Solute carrier 39 (zinc 
transporter) member 4 
2.81 
(p=2.5e-10) 
1.89 
(p=9.9e-08) 
1.65 
(p=2.1e-06) 
1.68 
(p=1.2e-06) 
 
To be considered part of a grouping, genes must have had a physiologic state p 
<0.05 and at least one tissue simple effect p <0.01.  Reported p-values are the 
tissue simple effect p-values.  The tissue simple effect p-value represents the 
comparison between Lactation and Control in the corresponding tissue.  For the 
purposes of assigning patterns, the significance cutoff for the remaining tissues’ 
simple effect p-values was set to p< 0.05.  Abbreviations used as in Table 3.1.  
*Gene is at the Extended confidence level. 
78 
 
Table 3.3. Top three pathways for overrepresentation in each tissue 
Liver    
Pathway Fisher’s Exact test 
p-value 
BH 
p-value 
Members 
 
Biosynthesis of steroids 3.50E-07 5.80E-05 ↑Dhcr7, ↑Fdft1,↑Hmgcr,↑Idi1, ↑Lss, ↑Mvd, 
↑Sqle 
LXR/RXR Activation 1.57E-04 1.30E-02 ↓Abcg5, ↓Abcg8, ↑Acaca, ↑Cyp7a1, ↓Hadh, 
↑Hmgcr, ↓Lcat 
Pentose/Phosphate  
Pathway 
3.01E-04 1.67E-02 ↑Aldoc, ↑G6pd, ↑Gpi, ↓H6pd, ↓Pgm5 
    
Duodenum    
Pathway    
Biosynthesis of steroids 1.13E-10 1.74E-08 ↑Dhcr7, ↑Fdft1, ↑Fntb, ↑Hmgcr, ↑Idi1, ↑Lss, 
↑Mvd, ↑Sc5dl, ↑Sqle 
Androgen and  
estrogen metabolism 
1.35E-04 1.04E-02 ↑Ftsj1, ↑Hsd11b1, ↑Hsd17b7, ↑Nsdhl, 
↓Srd5a2, ↓Ugt2b7 
Glycerolipid metabolism 1.46E-03 7.50E-02 ↓Cel, ↓Clps, ↓Glb1l2, ↓Pnlip, ↓Pnliprp1, 
↓Pnliprp2 
    
Jejunum    
Pathway    
T-Cell receptor signaling 1.68E-07 2.78E-05 ↓Bmx, ↓Cd8b, ↓Grap2, ↓Itk, ↓Malt1, 
↓Pik3cg, ↓Pik3r1, ↓Ppp3cc, ↓Prkcq, ↓Ptprc, 
↓Rasgrp1, ↓Trb 
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CD28 signaling in  
T helper cells 
1.17E-05 6.74E-04 ↓Grap2, ↓Itk, ↓Malt1, ↑Mapk9, ↓Pik3cg, 
↓Pik3r1, ↓Ppp3cc, ↓Prkcq, ↓Ptprc, ↓Trb 
TR/RXR activation 1.23E-05 6.74E-04 ↑Fga, ↑Gh1, ↓Klf9, ↑Ldlr, ↓Pik3cg, ↓Pik3r1, 
↓Thra, ↓Thrb, ↓Thrsp 
    
Ileum    
Pathway    
Biosynthesis of steroids 9.42E-08 1.71E-05 ↑Cyp24a1, ↑Dhcr7, ↑Fdft1, ↑Hmgcr, ↑Idi1, 
↑Mvd, ↑Sc5dl, ↑Sqle 
TR/RXR activation 3.16E-07 2.86E-05 ↑Fga, ↑Gh1, ↓Klf9, ↑Me1, ↓Nfcor2, ↓Pck1,  
↓Pik3c2b, ↓Pik3cg, ↓Pik3r5, ↓Ppargc1a, 
↓Thra, ↓Thrb 
Thrombopoietin signaling 4.85E-05 2.53E-03 ↓Irs2, ↓Pik3c2b, ↓Pik3cg, ↓Pik3r5, ↓Plcg1, 
↓Plcg2, ↓Prkce, ↓Prkcq 
 
The pathways with the three lowest p-values from Fisher’s exact test for 
pathways from IPA’s “Canonical Pathways” database for each tissue are 
reported here along with the corresponding p-value from a right-tailed Fisher’s 
exact test, the Benjamini-Hochberg (BH) adjusted p-value, and the genes within 
the pathway that showed differential expression within the respective tissue 
(Members).  Arrows in the Members column indicate the direction of change in 
lactating animals relative to controls. 
80 
 
  
Table 3.4.  ATP-Binding Cassette (ABC) transporters detected to be 
differentially expressed between Control and Lactating dams.  
Gene Symbol 
Transcript 
Cluster ID RL RD RJ RIL p<0.01 
Abca3 
7065486 0.888 
(p=0.138) 
0.931 
(p=0.329) 
0.99 
(p=0.874) 
0.8 
(p=0.007) IL 
Abca8a_predicted* 
7083965 0.567  
(p=7.0E-04) 
0.885 
(p=0.273) 
0.942 
(p=0.744) 
0.763 
(p=0.054) L 
Abcb1a 
7250393 0.63 
(p=0.001) 
0.663 
(p=0.002) 
0.652 
(p=0.002) 
0.697 
(p=0.005) L,D,J,IL 
Abcc5 
7089622 0.818 
(p=0.021) 
1.065 
(p=0.476) 
0.938 
(p=0.471) 
0.672 
(p=8E-05) IL 
Abcc6 
7051110 0.886 
(p=0.109) 
0.852 
(p=0.03) 
0.884 
(p=0.089) 
0.73 
(p=2.0E-04) IL 
Abcg2 
7254219 0.949 
(p=0.666) 
1.55 
(p=6.0E-05) 
1.049 
(p=0.613) 
1.203 
(p=0.049) D 
Abcg5 
7303106 0.321 
(p=3.0E-07) 
0.762 
(p=0.095) 
0.901 
(p=0.515) 
0.656 
(p=0.006) L, IL 
Abcg8 
7294657 0.297 
(p=4.0E-06) 
0.67 
(p=0.039) 
0.803 
(p=0.261) 
0.592 
(p=0.005) L, IL 
The p<0.01 column indicates in which tissues a change was detected. 
Abbreviations are as defined for Table 3.1.   *Gene is at the Extended level of 
confidence. 
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Additional files 
Additional File 3.1: Statistical analysis and statistical pattern matching 
results (Statistical_Analysis_and_Statistical_Pattern_Matching_Results.txt) 
Results from statistical pattern matching are reported as a .txt file. Results are 
reported for all 14,129 genes considered for statistical analysis, but genes that 
were not differentially expressed in any tissue are assigned a pattern of zero.  
Transcript_ID is an identifier associated with the gene analyzed.  The gene 
assignment entry was taken from the Affymetrix annotation file and displays 
which gene is associated with the given transcript ID.  Tissue p, physiological 
state p, and tissue*physiological state p correspond to the p-values associated 
with the tissue main effect, physiological state main effect, and the interaction, 
respectively.  p Liver, p duodenum, p jejunum, and p ileum represent the p-
values associated with the corresponding simple effects  Pattern indicates in 
which pattern a gene is detected.  A zero indicates no differential expression.  
Otherwise, patterns are assigned as described in the Methods.  Ratio liver, ratio 
duodenum, ratio jejunum, and ratio ileum represent the ratio of the mean of 
samples from lactating animals to the mean of samples from controls utilizing the 
untransformed microarray data. 
 
Additional File 3.2:  Benjamini-Hochberg false discovery rates 
(Benjamini_Hochberg_False_Discovery_Rates.txt) 
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False Discovery Rate corrections [102] for all genes studied is presented in .txt 
format.  Transcript_ID is an Affymetrix Identifier for each gene.  False discovery 
rates are provided for the tissue*physiological state interaction term and the 
overall physiological state effect.  Q-values were calculated as the number of 
false positives expected by chance (uncorrected p* total number of tests) divided 
by the total number of results with an equal or lower p-value. 
 
Additional File 3.3:  Histograms of p-values (Histograms_of_p_values.jpg) 
Histograms for A) tissue effect p-values, B) physiological state effect p-values, C) 
physiological state*tissue interaction p-values, and pairwise comparison p-values 
for D) the liver, E) duodenum, F) jejunum, and G) ileum presented as a .ppt file.  
While a large tissue effect was observed, a visible treatment effect (control vs. 
lactation) was also observed. 
 
Additional File 3.4: Volcano plots (Volcano_plots.pdf) 
Volcano plots comparing the log2 fold changes (reported as mean untransformed 
lactating intensity divided by untransformed mean control intensity) against the 
calculated pairwise comparison p-value for each individual tissue in .pdf format.  
Volcano plots are for A) Liver, B) Duodenum, C) Jejunum, and D) Ileum.  Each 
tissue responded differently to lactation.  The blue line indicates the significance 
cutoff of p< 0.01.  The number of differentially expressed genes were 420 in the 
liver, 337 in the duodenum, 402 in the jejunum, and 523 in the ileum, when an 
overall treatment main effect p-value cutoff of p<0.05 was incorporated.  Of 
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particular note is a series of genes that were strongly downregulated in the 
duodenum (Additional File 3.1 pattern -100; discussed in Results.)     
 
Additional File 3.5:  DAVID output (DAVID_output_file.txt) 
DAVID was utilized to test specific patterns from statistical pattern matching.  
Patterns were chosen based on similarity between tissues and were “Up in All 
Tissues”, “Down in all tissues”, “Up in all parts of small intestine”, “Down in all 
parts of small intestine”, “Up only in liver”, “Down only in liver”, and “Down only in 
duodenum”. Table truncated from output in DAVID.  Genes listed by Affymetrix 
transcript cluster ID, which may be referenced in Additional File 3.1. 
 
Additional File 3.6. Genes with decreased mRNA in all tissues 
(Genes_with_decreased_mrna_all_tissues.pdf)   
To be considered part of a grouping, genes must have a physiologic state p< 
0.05 and at least one tissue simple effect p <0.01.  Reported p-values are tissue 
simple effect p-values and represent the comparison between Lactation and 
Control in the corresponding tissue.  For the purposes of assigning patterns, the 
significance cutoff for the remaining tissue simple effect was set to p <0.05.  
Abbreviations used as in Table 3.1.  *Gene is at the Extended confidence level.   
 
Additional File 3.7: Biosynthesis of sterols in liver 
(Biosynthesis_of_sterols_in_liver.jpg)  
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Image from IPA representing the “Biosynthesis of Sterols” in the liver as a .jpg 
file.  Numbering system for enzymes in the pathway is taken from KEGG [160].  
Components of the cholesterol biosynthetic pathway include 1.1.1.34 (Hmgcr), 
2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 (Fdft1), 
and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7).  Red shading 
indicates increased mRNA during lactation from the corresponding gene.   
 
Additional File 3.8: Biosynthesis of sterols in duodenum 
(Biosynthesis_of_sterols_in_duodenum.jpg) 
Image from IPA representing the “Biosynthesis of Sterols” in the duodenum as a 
.jpg file.  Numbering system for enzymes in the pathway is taken from KEGG 
[160].  Components of the cholesterol biosynthetic pathway include 1.1.1.34 
(Hmgcr), 2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 
(Fdft1), and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7).  Red shading 
indicates increased mRNA during lactation from the corresponding gene. 
 
Additional File 3.9: Biosynthesis of sterols in jejunum 
(Biosynthesis_of_sterols_in_jejunum.jpg) 
Image from IPA representing the “Biosynthesis of Sterols” in the jejunum as a 
.jpg file.  Numbering system for enzymes in the pathway is taken from KEGG 
[160].  Components of the cholesterol biosynthetic pathway include 1.1.1.34 
(Hmgcr), 2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 
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(Fdft1), and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7).  Red shading 
indicates increased mRNA during lactation from the corresponding gene. 
 
Additional File 3.10: Biosynthesis of sterols in ileum 
(Biosynthesis_of_sterols_in_ileum.jpg) 
Image from IPA representing the “Biosynthesis of Sterols” in the ileum as a .jpg 
file.  Numbering system for enzymes in the pathway is taken from KEGG [160].  
Components of the cholesterol biosynthetic pathway include 1.1.1.34 (Hmgcr), 
2.7.1.36 (Mvk), 2.7.4.2 (Pmvk), 4.1.1.83 (Mvd), 5.3.3.2 (Idi1), 2.5.1.21 (Fdft1), 
and 1.14.99.7 (Sqle), 5.4.99.7 (Lss), and 1.3.1.21 (Dhcr7).  Red shading 
indicates increased mRNA during lactation from the corresponding gene. 
 
Additonal File 3.11. Genes regulated by Srebp proteins 
(Genes_Regulated_by_Srebp_proteins.pdf)   
Genes that increase expression in Srebp-1a overexpressing mice and Srebp-2 
overexpressing mice, and decrease expression in Scap knockout mice [87].  
Overrepresentation analysis showed that genes in this list occurred more 
frequently than expected by chance in the lists of differentially expressed genes 
(p<1X10-4
 
 in each tissue.) Abbreviations used as in Table 3.1.   *Gene is at the 
Extended confidence level.   
Additional File 3.12.  Members of the Slc superfamily (Slcs.pdf) 
86 
 
Table displaying members of the Slc superfamily.  The p<0.01 column indicates 
in which tissues a change was detected.  Abbreviations are as defined for Table 
3.1.  * Gene is at the Extended level of confidence.  a
http://www.bioparadigms.org/
Substrates taken from the 
SLC tables database ( ) 
 
Additional File 3.13: Canonical pathways in the liver 
(Liver_canonical_pathways.txt)   
This file contains the canonical pathways in IPA and the corresponding –log10 p-
values and the individual molecules that were detected as being in the list of 
overrepresented genes and part of each pathway (listed in the “molecules” 
column.)  FDRs for the individual pathways are shown in a separate series of 
rows underneath the –log10
 
 p-values.  This table shows results utilizing the list of 
differentially expressed genes in the liver.    
Additional File 3.14: Canonical pathways in the duodenum 
(Duodenum_canonical_pathways.txt) 
This file contains the canonical pathways in IPA and the corresponding –log10 p-
values and the individual molecules that were detected as being in the list of 
overrepresented genes and part of each pathway (listed in the “molecules” 
column.)  FDRs for the individual pathways are shown in a separate series of 
rows underneath the –log10
 
 p-values.  This table shows results utilizing the list of 
differentially expressed genes in the duodenum.    
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Additional File 3.15: Canonical pathways in the jejunum 
(Jejunum_canonical_pathways.txt) 
This file contains the canonical pathways in IPA and the corresponding –log10 p-
values and the individual molecules that were detected as being in the list of 
overrepresented genes and part of each pathway (listed in the “molecules” 
column.)  FDRs for the individual pathways are shown in a separate series of 
rows underneath the –log10
 
 p-values.  This table shows results utilizing the list of 
differentially expressed genes in the jejunum. 
Additional File 3.16: Canonical pathways in the ileum 
(Ileum_canonical_pathways.txt)  
This file contains the canonical pathways in IPA and the corresponding –log10 p-
values and the individual molecules that were detected as being in the list of 
overrepresented genes and part of each pathway (listed in the “molecules” 
column.)  FDRs for the individual pathways are shown in a separate series of 
rows underneath the –log10
 
 p-values.  This table shows results utilizing the list of 
differentially expressed genes in the ileum.    
Additional File 3.17: Thyroid pathway in liver (Liver_thyroid_pathway.jpg) 
Images from IPA for the TR/RXR pathway for the liver.  Red shading indicates 
increased mRNA amounts of the respective gene during lactation, and green 
shading indicates decreased amounts of mRNA.  
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Additional File 3.18: Thyroid pathway in duodenum 
(Duodenum_thyroid_pathway.jpg) 
Images from IPA for the TR/RXR pathway for the duodenum.  Red shading 
indicates increased mRNA amounts of the respective gene during lactation, and 
green shading indicates decreased amounts of mRNA. 
 
Additional File 3.19: Thyroid pathway in jejunum 
(Jejunum_thyroid_pathway.jpg) 
Images from IPA for the TR/RXR pathway for the jejunum.  Red shading 
indicates increased mRNA amounts of the respective gene during lactation, and 
green shading indicates decreased amounts of mRNA. 
 
Additional File 3.20: Thyroid pathway in ileum (Ileum_thyroid_pathway.jpg) 
Images from IPA for the TR/RXR pathway for the ileum.  Red shading indicates 
increased mRNA amounts of the respective gene during lactation, and green 
shading indicates decreased amounts of mRNA. 
 
Additional File 3.21: RT-PCR primers (RT_PCR_primers.pdf) 
Primer sequences for all genes analyzed by RT-PCR.   
 
 
 
© Antony Athippozhy 2011
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Chapter 4 
Detection of Differential Alternative Splicing in the Lactating Rat 
 
Introduction 
Lactating dams have increased energy demands.  Several physiologic changes 
occur in the animal to accommodate the need to provide for both themselves and 
their pups.  These changes include increased cholesterol synthesis [9], increased 
zinc absorption [74], increased bile acid pool size [10], and increased 
hydrophobicity of the bile acid pool [10].  In addition, a number of hormone 
signaling pathways are altered, including those for insulin, thyroid, and leptin [19].  
We have previously characterized the changes in mRNA expression in the liver 
and gastrointestinal tract (duodenum, jejunum, ileum) of the lactating dam 
compared to age matched virgin controls using an Affymetrix Rat Exon 1.0 ST 
microarray (Affymetrix, Santa Clara, CA) [164].   
In addition to changes in gene expression, alternative splicing is also a 
mechanism for controlling gene function.  To our knowledge, no work has been 
done to characterize changes in mRNA splicing during lactation.  One tool that 
has been developed to characterize differences in splicing between two different 
groups is the Exon Array.  In contrast to traditional 3’-expression arrays, probes 
in the Exon Array are designed to detect individual exons.  This allows for 
measurements of individual exons, and a comparison of exon expression 
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between two groups relative to the corresponding gene expression allows for 
identification of genes that are differentially spliced between the groups. 
In spite of the minimal work done to characterize splicing within the context of the 
lactating animal, the serum levels of several hormones that affect splicing are 
known to be altered.  Lactating rats are hypoinsulinemic [19], hypoleptinemic 
[19], and hyperprolactinemic when compared to nonlactating animals.  These 
pathways influence PI3K signaling [37, 38, 52, 54, 57, 58, 60, 61].  Insulin 
signaling can trigger differential splicing of protein kinase C β II through the PI3K 
pathway and ultimately through differential phosphorylation of SRp40, a member 
of the serine-arginine (SR) family of proteins which are often involved in the 
regulation of alternative splicing [68].  Likewise prolactin receptor activation leads 
to differential splicing of neuronal nitric oxide synthase (nNOS) in the rat anterior 
pituitary cell line, GH3 67[ ].  Consequently, differential alternative splicing through 
differential phosphorylation of SR proteins downstream of PI3k signaling seems 
likely in lactating animals.      
Several methods have been developed to analyze data from exon array chips.  
Two of these methods are ANOSVA [107] and MiDAS [97].  ANOSVA is a 
method based on a two-way ANOVA, utilizing the factor (i.e. source of variance) 
of interest and an exon effect as the two main effects.  A significant interaction 
term between the effect of interest and the exon is considered a positive test.  
This method operates under the model yijk=µ+αi+β j+γ ij+error, where yijk is the 
measured expression level for probe k in probeset i in experiment j, µ is a 
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baseline measurement, αi is the linear contribution of probeset i, β j is the linear 
contribution of the other factor, and γij
165
 is the interaction effect.  In the presence of 
differential alternative splicing, the addition of a splicing event creates a situation 
where the sum of µ, αi, and βj do not fully explain the model, and the difference is 
explained in the interaction term.  However, problems have been reported with 
this model, as an Affymetrix white paper discussing the method described that it 
“did not yield good performance” but specific flaws were not discussed [ ].  
Also, because the test is performed for the entire gene, the method does not give 
a direct measure of where the potential splice sites occur. 
Another method used to detect differential alternative splicing is called MiDAS 
[97].  This method utilizes “gene normalized intensities” to identify where splicing 
has occurred.  The gene normalized intensities are calculated as the ratio of an 
individual exon’s expression to an estimate of the gene’s overall expression.  If a 
significant difference occurs between “gene normalized intensities” for a given 
exon, then that exon may be differentially spliced.  Analysis is often done by 
utilizing a t-test on the gene normalized intensities [97].  In some cases, this 
method has reported low validation rates, as there are several well-known 
sources of false positives in exon microarrays.  These include failure of a probe 
to hybridize to its target cDNA, hybridization to nontarget cDNAs, and a gene not 
being expressed in one of the treatment groups [97].  Because of these 
problems, adequate prefiltering before analyzing the data is a necessity [97].   
92 
 
We have utilized a combination of ANOSVA and MiDAS to detect differential 
splicing.  We have characterized differential alternative splicing in the liver, 
duodenum, jejunum, and ileum of lactating rats compared to age matched virgin 
controls by running ANOSVA to identify differentially spliced genes, followed by 
MiDAS to identify differentially spliced exons.   
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Results 
ANOSVA Overestimates p-values 
The physiologic state*probeset interaction p-values were plotted as histograms 
for each tissue (Figure 4-2).  In the absence of any significant interactions (and 
under the assumptions of the algorithm, in the absence of alternative splicing), 
the interaction p-values would be expected to be normally distributed.  However, 
histograms of the p-values show that p-values were biased toward one (1) in 
each tissue, although in the ileum, there was both a bias toward zero (0) and one 
(1).  This indicates that the ANOSVA method is in general, overestimating the p-
values, as the expected uniform distribution of nonsignificant results was not 
present.  Histograms of MiDAS p-values (Figure 4.3) appeared to follow a similar 
trend, but the effect was much less pronounced, since there were multiple exons 
for each gene.     
Number of genes that tested positive in each tissue for alternative splicing 
Because low validation rates have been reported for microarray experiments, 
and validation can be a time-consuming and costly endeavor, we chose a 
relatively stringent cutoff at the level of ANOSVA (FDR=0.05).  In three of the four 
tissues, very few genes (i.e., less than 20) were detected as positives (Tables 
4.1-4.3).  Given that an FDR of 0.05 indicates that approximately 1 in 20 genes 
are false positives, and fewer than 20 genes appear in these lists, it is plausible 
that some of these genes tested positive by chance.  However, the ileum 
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displayed a much higher incidence of positive tests (Additional File 4.1).  This is 
indicative of a unique event occurring within the ileum, as all tissues were 
analyzed using the same model.   
UGTs Test Positive for Alternative Splicing 
In both the liver and the ileum, the gene associated with the UDP 
glucuronosyltransferase 1 family polypeptide a (UGT1a) tested positive for 
alternative splicing.  The UGT1a differ by usage of an alternative first exon.  The 
splicing events that tested positive by the microarray were associated with 
probesets that match the alternative first exons.  In the liver, probesets 6347739 
and 6443473 tested positive for differential alternative splicing, while in the ileum, 
no individual probesets tested positive in MiDAS, although the ANOSVA for the 
gene gave a significantly low p-value.  By using University of California, Santa 
Cruz (UCSC) genome browser [166, 167] to align the target sequence against 
the genome, we identified probeset 6347739 as being associated with the first 
exon of Ugt1a7c, and probeset 6443473 as being associated with the first exon 
of Ugt1a6.  
Alternative Splicing of Abcg8 
Initial analyses of the extended dataset prior to filtering out poorly expressed 
probesets resulted in a larger number of positive tests.  Within this dataset, 
Abcg8 was flagged as a likely candidate for alternative splicing in the liver only 
(positive at FDR<0.05; Figure 4.4).  RT-PCR detected a splice variant that was 
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present in lactating samples, and this variant was sequenced.  (Additional File 
4.2).  Only one transcript variant was sequenced, although others were identified 
in the RT-PCR products.     
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Discussion 
A Series of Events Occur in the Gastrointestinal Tract That is Unique to the 
Ileum 
 
The same algorithm was utilized to detect the possibility that lactation triggers 
changes in alternative splicing in each tissue.  In three of the tissues, very few 
positive tests were detected.  However, the ileum showed substantially more 
positive alternative splicing events (89 in the ileum, less than 20 in each of the 
other tissues).  Although events such as alternative start site and stop site usage 
would also test positive as alternative splicing events, this indicated that a unique 
physiologic event was occurring in the ileum of lactating rats that was not 
occurring in the liver, duodenum, or jejunum.  Based on differences in serum 
hormone levels reported in lactation, we had reason to hypothesize that levels of 
alternative splicing in the gastrointestinal tract were altered during lactation.  
Thus, changes in signaling via the PI3k/Akt pathway could affect splicing 
mechanisms.  However, in three of the four tissues, the number of splicing 
events detected by the microarray chip was small.  Alternative splicing events in 
any of these tissues in the lactating animal have not been characterized 
previously.  Further work needs to be done to characterize what changes in the 
local environment of the ileum might trigger differences in alternative splicing that 
are unique to the ileum when compared to the other more proximal parts of the 
small intestine and the liver.   
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Abcg8 is Differentially Spliced in the Liver of Lactating Dams, but not in the 
Small Intestine 
 
Our previous analyses [5] showed that Abcg8 is differentially expressed in the 
livers of lactating rats.  mRNA and protein levels are significantly decreased, and 
functional heterodimer was not detectable in livers of lactating dams.  Initial 
analyses of the microarray data for the detection of alternative splicing prior to 
filtering out poorly expressed genes indicated that Abcg8 might be differentially 
spliced in the liver of lactating animals.  From the plots of probeset intensity, the 
probesets in the liver of lactating rats show a clearly different pattern of 
expression than in any other tissue or physiologic state group (Figure 4.4).  We 
investigated the cause of the unique expression pattern in these livers.  RT-PCR 
identified a transcript variant within the lactating liver samples.  This variant was 
sequenced and found to be missing part of exon 4, all of exons 5,- 8, and part of 
exon 9.  Blasting the sequence of the clone against the rat genome identified the 
best match was Abcg8, with several regions having 100% identity and others 
varying only by a single nucleotide mismatch or a gap.  Comparing the 
determined sequence against NCBI’s NM_130414 mRNA entry and NP_569098 
protein entry, it was determined that this transcript most likely would not have 
been able to produce functional protein.  In addition to the possibility that the 
transcript’s product may not have been able to form a dimer with Abcg5, this 
transcript would likely not include many key features of the transporter, including 
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the Walker B motif in the nucleotide binding domain where ATP is bound.  This 
result indicated that within the lactating liver, incomplete transcripts of Abcg8 
were being formed, and these transcripts may not be able to form the functional 
protein, providing further description for the lack of functional Abcg8 protein 
detected in the liver of lactating dam. This, in addition to the substantially 
decreased amounts of Abcg8 mRNA, suggested that control of Abcg8 levels in 
lactating dams happened at least in part at the level of transcription.  As we have 
described in Chapter 3, loss of Abcg5/g8 requires that cholesterol be secreted 
into bile through an alternative mechanism rather than through transport 
mediated by the Abcg5/Abcg8 heterodimer.  Abcg5 was not detected to be 
differentially spliced in the same manner, but failure to produce functional Abcg8 
interferes with the formation of functional heterodimer [168].  Abcg8 was 
removed from the final analysis in liver due to its already low expression in liver 
samples from lactating animals. 
 
The Gene Associated with Members of the Ugt1a Family of Enzymes Shows 
Differential First Exon Usage in the Microarray Data in Both the Liver and 
the Ileum 
 
mRNA associated with the Ugt1a proteins tested positive for differential 
alternative splicing in the liver and ileum.  The Ugt1a locus codes for a family of 
proteins that differ in their amino termini, but have consistent carboxy termini.  
This is accomplished through utilization of a variable first exon, followed by the 
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consistent usage of exons 2-5.  These enzymes are responsible for transferring 
glucuronic acid to the substrate, which generally creates a water soluble, 
biologically inactive product.  These enzymes are important in both elimination of 
endogenous substrates and various drugs.  A review of many example drug 
substrates can be found in Kiang et al [169].   
 
Because the microarray makes measurements on each individual exon, 
differences in the usage of the differential first exon can be identified when 
testing for alternative splicing.  In both the liver and the ileum, the Ugt1a locus 
was identified as a site of “differential alternative splicing”, and further analyses 
revealed that the detected sites were located in the alternative first exons.  In the 
liver, Ugt1a6 and Ugt1a7 were identified as having higher expression of the 
corresponding first exon present in the lactating samples compared to controls, 
while in the ileum, no forms were found differentially expressed by MiDAS, but 
Ugt1a3 and Ugt1a5 appeared to have slightly decreased expression of mRNA 
from the respective first exons in lactating dams (Figure 4.5).  However, the 
constituitive exons 2-5 did not display a change in expression.  These results 
suggested that drug metabolism may be altered in lactating dams.  For example, 
Ugt1a6 can metabolize acetaminophen.  The results from Ugt1a6 were 
consistent with reports of transgenic mice expressing the human UGT1A locus 
having higher levels of UGT1A6 post-partum [170].  Also, Ugt1a6 mRNA and 
protein have been shown to be increased in lactating rats and in rats treated with 
ovine prolactin [94], indicating that our results regarding Ugt isoforms were 
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consistent with previous literature.   Further studies need to be performed to 
elucidate how differences in Ugt levels actually influence drug metabolism. 
 
Other Genes Detected to be Differentially Spliced and Biological Roles 
 
Because the ileum showed a substantially higher number of splicing events 
compared to the other three tissues, we chose to focus on it for further analyses.  
Additional File 4.1 displays genes that tested positive in the ileum and 
corresponding physiologic state*probeset_ID interaction p-values as calculated 
by Partek.  Angiotensin converting enzyme 2 (Ace2) showed the lowest p-value 
for alternative splicing in ileum using the two-way ANOVA model in Partek 
(Figure 4.6).  MiDAS results, in conjunction with plotting exon intensities as a 
function of chromosomal position in both groups, revealed that probeset 
5728701, which maps to the 3’ end of exon 9 in the UCSC genome browser, was 
a possible site of differential alternative splicing, as a drop in both groups 
occurred, but the magnitude of the drop was greater in the control group.  This 
would indicate that proportionately fewer transcripts contained the exon in control 
than lactating animals.  In the duodenum and jejunum, a large decrease in 
expression of the probeset was observed, but there was no statistically 
significant difference in the gene normalized intensities between the groups.  
These results indicate that the splicing event was unique to the ileum.   
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Ace 2 catalyzes conversion of angeniotensin II into the inactive heptapeptide 
Ang1-7.  Active angiotensin II is responsible for triggering increased blood 
pressure [171] and secretion of aldosterone, which leads to sodium retention 
[172].  The degradation of angiotensin II prevents further activity, meaning that 
ACE2 plays a key role in regulating blood pressure and sodium levels.  
Furthermore, the heptapeptide Ang1-7 can inhibit angiotensin II activity [173].   
 
Using BLAT [174] against the Nov. 2004 (Baylor 3.4/rn4) assembly [175] to map 
the location of probeset 5728701’s target sequence in the UCSC genome 
browser did not reveal any ESTs for Ace 2 that were spliced in the corresponding 
region.  The most likely explanations for the results observed are that the probe 
hybridizes poorly, as marked by the large decrease in intensity relative to other 
probes in the same gene in all parts of the small intestine, or that the splicing 
event was real and was unique only to the ileum.  The region corresponding to 
probeset 5728701 matches the mRNA refseq entry NM_001012006 from 
nucleotides 1301 to 1326.  This was consistent with amino acids 434-442 in the 
translated protein, which can also be viewed in the NCBI refseq entry 
NM_001012006 or in the protein entry NP_001012006.  This region was included 
with the peptidase region from amino acids 22-612, but was not associated with 
any active sites within the protein entry, which map to amino acids 345-348,374-
375,378,382,401-402,449,503,505,512, and 515.  Consequently, if this splice 
form interfered with function of the full protein, it would likely be from a 
conformational change through missing residues near the active sites; the 
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closest active site was threonine 449.  Because this splice form retains its active 
sites and its transmembrane domain, the splice variant may still be biologically 
active, however this requires independent verification.   
 
DAVID [105] was used to identify similarities amongst genes that were 
differentially alternatively spliced in the list of 89 genes detected in the ileum.  
Amongst these, four members of the renin angiotensin (p=5.4X10-4) pathway 
were detected, including the previously mentioned Ace2.  Figure 4.7 shows the 
KEGG renin angiotensin pathway, as displayed from within DAVID.  Members 
marked with stars were members of the renin angiotensin pathway. The other 
three members were alanyl (membrane) amino peptidase (Anpep), leucyl/cystinyl 
peptidase (Lnpep), and membrane metallo endopeptidase (Mme).   
 
Seventeen members of the SP_PIR_Keywords group “alternative splicing” tested 
positive for differential alternative splicing (p=4.1X10-3
 
) (Table 4-4).  Amongst 
these was the Ugt1a locus, which produces different proteins based on usage of 
an alternative first exon and is discussed in detail above. These are proteins that 
have been previously associated with alternative splicing.  
In the liver, probesets associated with Ugt1a6 and Ugt1a7 were detected as 
differentially spliced.  This suggested possible differences in improved ability to 
conjugate phenols, such as acetaminophen.  In the rat, Ugt1a6 and Ugt1a7 are 
co-regulated through Ahr [95], suggesting that these results may have been a 
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response to the same mechanism.  However, this result is not directly 
transferable to humans, as humans do not express Ugt1a7 in the liver [176]. This 
result was consistent with previous reports that Ugt1a6 mRNA and protein ares 
increased during lactation and in response to prolactin [94]. 
 
Using a network drawn around Ahr in Ingenuity Pathways Analysis (Ingenuity 
Systems, www.ingenuity.com), we found that four genes differentially expressed 
in the liver would be influenced by Ahr.  Two changes were consistent with 
increased Ahr activity: increased Cyp1a1 [177] and decreased Serpina7 [178].  
The other two changes that would be influenced by Ahr activity occured in the 
direction opposite of the expected change.  Hmgcr [179] transcription was 
increased [164]  and Phophoenolpyruvate carboxykinase 1 (Pck1, also known as 
Pepck), a key regulator in gluconeogenesis, transcription was decreased [178].  
The inconsistent changes were easily explained by the change in the lactating 
rats’ metabolic state, as discussed in Chapter 3.   
 
RT-PCR Validation of Alternative Splicing Events 
 
The following factors should be considered when determining which alternative 
splicing events are likely true positives.  First, does the exon in question show a 
substantial difference in intensity and gene normalized intensity from the other 
exons?  Low variance across the measurement could lead to a statistically 
significant result, but if the cause of that low variance was not a direct result of 
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the treatment, then the answer would be a false positive.  Relative expression of 
the exon to the other exons in the gene may be an indication of actual alternative 
splicing, since it should be expressed at a lower level than constitutively 
expressed exons, although probe affinity should be accounted for when 
comparing across exons.   
 
Another factor to take into account when choosing genes for which to validate 
splicing events is the presence of existing known splicing events [97].  The 
existence of known exons indicates that the transcript variant in question exists, 
and the only thing needed to be validated is the relative level of transcripts in 
each treatment.  In some cases, the experimenter may be interested in novel 
splice variants or the animal model’s transcriptome has been poorly sequenced.  
In these cases, the experimenter may need to consider if consensus or 
alternative acceptor and donor sites exist within the sequence.  The donor and 
acceptor sites indicate the 5’ and 3’ ends of the splice site, respectively [180].   If 
the region of interest is on the 5’ or 3’ end of the message, alternative initiation 
and poly adenylation sites may need to also be considered.   
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Conclusions 
 
The results of this study are consistent with previous findings that Ugt1a6 
expression is increased in the liver of lactating dams. Our results indicated that 
Ugt1a7 may be regulated in a similar manner.  We have detected an mRNA 
transcript variant of Abcg8 in the liver that further indicates that control of the 
levels of functional Abcg5/Abcg8 heterodimer are controlled at the level of 
mRNA.  Our results also suggested possible differential alternative splicing of 
four members of the renin-angiotensin pathway, especially Ace2, which is key in 
inhibiting the renin-angiotensin pathway.   Further work needs to be performed in 
order to validate exactly how splicing events are regulated in the gastrointestinal 
tract in lactating animals when compared to virgins.  For example, the ileum was 
more responsive to changes in alternative splicing than the liver, duodenum, or 
jejunum.  Current methods for identifying differential alternative splicing, 
particularly ANOSVA and MiDAS need to be refined to be applicable to the 
microarray dataset, as p-values did not form a uniform distribution for non-
significant tests, indicating that assumptions within the model were violated. We 
have specified a minimal difference filter in order to attempt to rectify some of the 
false positives.  Finally, RT-PCR using primers flanking probable splice sites for 
genes that were strong candidates for differential splicing, such as Ace2 in the 
ileum needs to be performed.  Validating the RT-PCR results will describe how 
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well the additional filters work, as well as provide insights regarding the biology of 
the lactating animal, as differential splice variants may play different biological 
roles.   
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Materials and Methods 
Animals 
The data used here were obtained as described in Chapter 3 and published 
recently [164].  Briefly, sixteen Sprague-Dawley rats at day 10-11 of lactation and 
sixteen age matched virgin controls were obtained from Harlan (Indianapolis, IN). 
All animals were sacrificed at 16 h (10 h of light on a 12 hour light/dark cycle; 4 
PM), and the liver, duodenum, jejunum, and ileum removed for total RNA 
extraction from each tissue.  The integrity of all RNA samples was verified by an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).  Animal 
protocols were conducted in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and were approved by 
the Institutional Animal Care and Use Committee of the University of Kentucky.  
Each rat was assigned to one of four pools within the respective physiologic state 
(treatments; four control pools and four lactating pools.)  Pooled RNA samples, 
consisting of the RNA from the four rats within the same group, were created for 
each tissue, with individual rats composing the pools consistent across tissues. 
resulting in the use of 32 chips (4 tissues X 2 “treatments” X 4 pools).  Samples 
were prepared and processed according to the manufacturer’s instructions by the 
University of Kentucky Microarray Core Facility (Lexington, KY) 
Data Filtration 
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The data were filtered in order to reduce the risk of false positives.  Affymetrix 
Expression Console software (Affymetrix, Santa Clara, CA) was used to perform 
the Robust Mutichip Averaging (RMA) [98, 99] algorithm on each tissue 
separately on the “Core” dataset.   For example, the eight chips associated with 
the liver were analyzed at the same time, but were analyzed separately from the 
eight chips associated with the duodenum.  During these calculations, Detection 
Above Background (DABG) values were calculated.  A DABG of less than 0.01 
was considered a positive test, and probesets (treated as exons for the purposes 
of the calculations) with DABG values of less than 0.01 were considered present 
on the respective chip.  If a probeset was present in at least three of four chips in 
control or lactating groups, the exon was considered present in that group.  If a 
probeset was not considered present in both groups, it was removed from 
analysis for determining differential splicing.  A column determining whether a 
given probeset was present for a given group (control or lactation) (in which case 
a value of “1” was assigned) or absent (in which case a value of “zero” was 
assigned) was added to the spreadsheet.  A second presence call was 
generated with a value of “1” indicating that the probeset was present in at least 
one group, and a value of “0” indicating the probeset was present in neither 
group.  This was repeated for probeset intensity, where a cutoff of the log2 RMA 
intensity was 4 rather than applying a DABG cutoff, and the presence/absence 
assignment was done in the same way.  The Affymetrix Rat Exon 1.0ST 
annotation file (raex-1_0-st-v1-na30.rn4) was also used to identify genes that 
have been characterized as risks of cross-hybridizing to nontarget cDNAs.  Any 
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exon identified as a risk was removed from analysis.  Affymetrix has identified 
probesets that may have issues with cross-hybridizing to cDNA other than the 
intended target.  In the Affymetrix annotation file, a value of “1” in a column 
labeled “Crosshyb_type” is assigned to probesets that are not likely at risk to 
cross-hybridize to nontarget cDNA.  Any value other than “1” in the annotation file 
under the column “Crosshyb_type” was determined to be a risk for cross-
hybridization.  In our dataset, a column containing a “1” for the row if the probeset 
in question was determined not likely to cross-hybridize and a “0” if the probeset 
was likely to cross-hybridize was created.  The product of the three 
presence/absence calls was used to determine if a probeset was present or 
absent.  Presence calls were made for each group and overall.  A gene was 
considered present overall if both the DABG cutoff and the intensity cutoff 
indicated half of the probesets were present in both control and lactation.     
JMP Genomics (SAS Institute Inc, Cary, NC) was used to summarize each of the 
probeset_IDs into transcript clusters (genes).  The sum of present exons in 
control or lactating samples were calculated for each gene.  If 50% of the exons 
in a given gene were not expressed in either control or lactation, the gene was 
removed from analysis.  An intensity cutoff at the gene level was applied in a 
similar manner to the intensity cutoff applied at the exon level.  If a gene 
expressed an intensity of at least four in three of the four chips within a group, it 
was considered present for the group; otherwise, it was considered absent for 
that group.  This time, a gene needed to be present in both groups to be 
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considered present overall.  These steps were repeated for each tissue.  
Presence/absence calls were used to generate a text file that contained a list of 
probesets to be used in the final analysis.     
Detection of Differentially Spliced Genes 
Affymetrix .CEL files were uploaded into Partek Genomics Suite ©2011 (Partek 
Incorporated, St. Louis, MO) [181], and the RMA algorithm was utilized to treat 
the data.  After implementing the RMA algorithm, a list of probesets to be utilized 
according to the filtration procedures described above was used to filter the 
dataset.  Each tissue was loaded separately into Partek, and the RMA algorithm 
was performed separately for each tissue.  Partek was then used to run a two 
way ANOVA treating physiologic state and exon as the two main effects.   The 
physiologic state*exon interaction term was used as an estimate for the likelihood 
that a gene was differentially spliced within lactating animals compared to virgin 
controls.  A false discovery rate (FDR) was calculated by Partek and a value of 
0.05 was used as a cutoff for a positive alternative splicing test in each tissue.     
Detection of Differential Splice Sites 
RMA values of exon and gene intensities from the RMA algorithm performed in 
the Affymetrix Expression Console software was used to calculate “gene 
normalized intensities”.  The gene normalized intensity was defined as the RMA 
calculated intensity value of a probeset_ID divided by the intensity value of the 
corresponding gene level intensity.  A t-test for these values with respect to 
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physiologic state was performed for each exon within a gene that tested positive, 
and this procedure was repeated for each tissue.  A p < 0.01 in MiDAS was 
considered a positive test for differential splicing of a given exon.  The t-tests 
were performed in Microsoft Excel (Microsoft Corporation).  Graphs of exon level 
intensities as a function of treatment and exon for genes that tested positive were 
also investigated in Partek.  Because low variance appeared to be an issue in 
some positive tests, we also specified that a minimal difference of 0.5 on a log2 
scale between mean exon intensities be present.  The minimal difference filter 
would filter out situations where poor probe expression occurred but failed the 
presence/ absence filter.  There were other cases in which the difference 
between exon expression appeared minimal when the data were displayed 
graphically (Figure 4-1), and consequently only positive tests that also displayed 
a large difference (0.5 on a log2
RT-PCR and Sequencing of an Abcg8 Splice Variant 
 scale) were considered positive for the purposes 
of detecting the locations of potential splice sites.   
RT-PCR was performed on a Roche Light Cycler 280 instrument (Roche Applied 
Sciences, Manheim, Germany).  The forward primer for Abcg8 was 
ATGGCTGAGAAGACCAAAGAGG, and the reverse primer was 
 ATCATTGTCCTCAGTCGGGCTC.  Samples were taken from the original RNA 
samples from the liver used for the microarray.  RT-PCR products were 
separated on an agarose gel.  A single RT-PCR product was extracted that was 
detected in the lactating sample, and this product was sequenced at MWG 
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biotech (Huntsville, AL).  This portion of the study was carried out by Dr. 
Tianyong Zhao in our laboratory.   
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Figures 
 
 
Figure 4.1: A sample case of low variance leading to a likely false positive in 
MiDAS.   Lnpep tests positive by ANOSVA, and three probesets test positive at 
p<0.01 in MiDAS.  Although these probesets have low p-values due to low within-
group variance, validation of an actual splicing event and its biological relevance 
at these sites would be difficult.  The figure was extracted from Partek genomics 
suite, with probesets that test positive for MiDAS being circled.  The circled 
exons were removed from the list of positive exons if a minimal difference of 0.05 
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between probeset intensities was enforced.  Intensities (right axis) are plotted as 
a function of chromosome position (bottom axis).  Chromosome number is listed 
on the left axis.  The two Refseq transcripts are listed across the top 
(NM_001113403 and NM_133574), with boxes representing individual exons. 
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Figure 4.2: Histograms of alternative splicing p-values calculated by Partek.  
Values show a bias toward p=1.0, suggesting that underlying assumptions within 
the model are violated.  On the x-axis are p-values and the y-axis represents the 
number of genes at the corresponding p-value.   A. Liver, B. Duodenum, C. 
Jejunum, and D. Ileum.  The darker shaded region represents p<0.01. 
A 
Liver 
B 
Duodenum 
C 
Jejunum 
D 
Ileum 
116 
 
 
 
Figure 4.3:  Histograms of MiDAS p-values for probesets detected as present on 
the microarray chips in the respective tissue (A. Liver, B. Duodenum, C. 
Jejunum, and D. Ileum).  On the x-axis are p-values and the y-axis represents 
the counts of probesets at the corresponding p-value.  In the liver, duodenum, 
and jejunum, an upward shift appears toward p=1, indicating that nonsignificant 
results were not uniformly distributed, suggesting some underlying assumptions 
regarding the MiDAS algorithm have been violated.   Darker shaded regions 
represent p<0.01. 
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Figure 4.4: Abcg8 probeset expressionin A. Liver, B. Duodenum, C. Jejunum, 
and D. Ileum.  Data compare probeset expression in  lactation (blue line) against 
control (red line) before setting filters to remove absent exons and genes.  The 
liver responds substantially differently to lactation at the level of individual 
probesets than the other tissues.  This has been validating using RT-PCR.  .  
Intensities (right axis) are plotted as a function of chromosome position (bottom 
axis).  The left axis lists the chromosome number.  Along the top is the NCBI 
refseq entry for Abcg8, with boxes representing individual exons. 
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Figure 4.5:  Probeset expression of the Ugt1a locus in liver (A) and ileum (B).  In 
the liver, genes that tested positive by MiDAS at p<0.01 are circled.  In the ileum, 
no probesets passed this test.  In the liver, exons associated with Ugt1a6 and 
A 
B 
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Ugt1a7 show increased expression during lactation (blue line) compared to virgin 
controls (red line).   
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Figure 4.6:  Ace2 probeset expression in duodenum (A), jejunum (B), and ileum 
(C).  Individual probeset intensities are plotted as a function of chromosome 
position as indicated by Partek.  Each tissue displays a substantially lower 
expression for probeset 5728701, but only in the ileum was significant differential 
relative expression detected between control (red line) and lactation (blue line).   
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Figure 4.7: The renin angiotensin system from KEGG [126, 160, 161] as 
displayed in DAVID.  Stars denote specific enzymes detected as differentially 
alternatively spliced within the pathway.  Using the list of genes differentially 
alternatively spliced in the ileum, the renin angiotensin pathway displays a p-
value of 5.4X10-4. 
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Tables 
 
Table 4-1: Genes detected to be differentially spliced in the liver of lactating 
animals  
 
Gene 
Symbol 
# of 
probesets 
Transcript 
Cluster ID RefSeq alt splicing p 
Bhmt 7 7202449 NM_030850 1.07E-08 
Cdc42 8 7292247 AF205635 1.79E-08 
Cpa1 9 7252157 NM_016998 1.07E-07 
Gck 13 7127894 NM_012565 1.55E-07 
Lss 26 7221620 NM_031049 1.63E-06 
Ugt1a 23 7357340 NM_201425 1.19E-05 
Slc6a13 14 7258065 NM_133623 2.59E-05 
Comt 6 7089781 NM_012531 3.64E-05 
      
 
ANOSVA was utilized to identify genes that were likely differentially spliced with a 
cutoff of an FDR of 0.05. Bhmt: Betaine-homocysteine methyltransferase; Cdc42: 
cell division cycle 42; Cpa1: Carboxypeptidase A1; Gck: glucokinase; Lss: 
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Lanosterol synthase; Ugt1a: UDP glucuronosyl transferase 1 family; Slc6a13: 
Solute carrier family 6 member 13; Comt: Catechol-O-methyltransferase.  “Gene 
symbol” is the NCBI official gene symbol for the respective transcript, “# of 
probesets” indicates the number of probesets associated with the transcript, 
“Transcript Cluster ID” indicates the Affymetrix transcript cluster ID associated 
with the transcript, “RefSeq” identifies the Refseq entry for the corresponding 
transcript, and “alt splicing p” indicates the interaction p-value between probeset 
ID and physiologic state effect given by Partek. 
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Table 4-2: Genes were detected to be differentially spliced in the duodenum 
of lactating animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANOSVA was utilized to identify genes that were likely differentially spliced with a 
cutoff of an FDR of 0.05. Reg1a: Regenerating islet derived alpha 1; Ebp4.1l3: 
Erythrocyte membrane protein band 4.1-like 3; Ppap2a: Phosphatidic acid 
phosphatase type 2A; Slc34a2: Solute carrier family 34 member 2; Ctrl: 
Chymostrypsin-like; Ptprh: Protein tyrosine phosphatase receptor type H; Abcb9: 
ATP-binding cassette subfamily b member 9; Fbxo8: F-box protein 8; Atf2: 
Activating transcription factor 2.   Column headings are as used in table 4.1.   
Gene 
Symbol 
# of 
probesets 
Transcript 
Cluster ID 
RefSeq alt splicing p 
Reg1a 6 7255179 --- 9.19E-10 
Epb4.1l3 28 7358708 NM_053927 3.57E-08 
Ppap2a 7 7189673 NM_022538 1.36E-06 
Slc34a2 15 7126150 NM_053380 1.48E-06 
Ctrl 7 7184989 NM_054009 1.77E-05 
Ptprh 14 7028616 D45413 1.95E-05 
Abcb9 12 7098148 NM_022238 2.87E-05 
Fbxo8 8 7150879 --- 4.50E-05 
Atf2 12 7240317 --- 7.32E-05 
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Table 4-3: Genes detected to be differentially spliced in the jejunum of 
lactating animals. 
 
Gene 
Symbol 
# of 
probesets 
Transcript 
Cluster ID RefSeq 
alt splicing 
p 
Acta1 7 7186461 NM_019212 6.10E-09 
Alpi2 15 7357124 NM_022680 3.82E-08 
LMO7 31 7134690 NM_001001515 4.38E-06 
Maob 16 7373289 NM_013198 2.09E-05 
Ppap2a 7 7189673 NM_022538 4.01E-05 
Tpm4 8 7149580 NM_012678 7.02E-05 
    
 
 
ANOSVA was utilized to identify genes that were likely differentially spliced with a 
cutoff of an FDR of 0.05.  Acta1: actin alpha 1, Alpi2: Alkaline phosphatase 3;   
LMO7: Lim domain 7; Maob: monoamine oxidase b; Ppap2a: Protein tyrosine 
phosphatase type 2A; Tpm4: Tropomyosin 4.   Column headings are as used in 
Table 4.1.   
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Table 4.4: Genes found in the “alternative splicing” Sp-Pir keywords 
category.   
 
Transcript_Cluster_ID Gene Name 
7314252 
ATPase, Ca++ transporting, plasma 
membrane 1 
7137113 ERO1-like (S. cerevisiae) 
7094780 
ST6 beta-galactosamide alpha-2,6-
sialyltranferase 1 
7357340 
UDP glucuronosyltransferase 1 family, 
polypeptide A2; UDP glucuronosyltransferase 
1 family, polypeptide A5; UDP 
glycosyltransferase 1 family polypeptide A3; 
UDP glucuronosyltransferase 1 family, 
polypeptide A6; UDP glucuronosyltransferase 
1 family, polypeptide A9; UDP 
glycosyltransferase 1 family, polypeptide A8; 
UDP glucuronosyltransferase 1 family, 
polypeptide A7C; UDP 
glucuronosyltransferase 1 family, polypeptide 
A1 
7070578 acetyl-coenzyme A carboxylase alpha 
7083901 archaelysin family metallopeptidase 2 
7085242 casein kinase 1, delta 
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7292247 cell division cycle 42 (GTP binding protein) 
7353844 interleukin 1 receptor-like 1 
7146425 neuregulin 1 
7160039 Optineurin 
7033968 
phosphatidylinositol binding clathrin assembly 
protein 
7192686 phospholipase D1 
7289791 sterol carrier protein 2 
7091588 synaptojanin 1 
7347403 transcription factor 12 
7346991 tropomyosin 1, alpha 
 
Transcript_Cluster_ID refers to the Affymetrix transcript clusters that identify 
each gene on the exon array, and gene name identifies the genes by name.   
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Additional File 4-1:  Differentially_spliced_genes_ileum.txt.  ANOSVA was 
utilized to identify genes that were likely differentially spliced with a cutoff of an 
FDR of 0.05.  Column headings are as used in Table 4.1.  Gene assignment is a 
detailed description of the full name of the gene, and contains the refseq entry 
and gene symbol.  Given in .txt format. 
 
Additional File 4-2:  Abcg8_sequence.txt Sequence of both the full Abcg8 
transcript and the detected splice variant.  Given in .txt format. 
 
 
 
 
 
 
 
 
 
 
© Antony Athippozhy 2011
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Chapter 5 
Discussion, Additional Studies, and Conclusions 
Cholesterol Biosynthesis is upregulated at the mRNA level in lactating 
dams 
Analysis of the rat exon array data revealed several changes at the mRNA level 
that aid in defining the physiology of the lactating rat.  Fisher’s exact test in 
Ingenuity Pathways (IPA) (Ingenuity Systems, www.ingenuity.com) identified 
pathways that were altered at day 10, 16h lactating rats when compared to virgin 
controls.  The most evident change was increased mRNA from genes in the 
cholesterol biosynthetic pathway.  Lactating rats need cholesterol both for 
secretion into the milk as well as to account for the increased production of bile 
acids [10].  3-Hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), the rate 
limiting step of cholesterol synthesis was upregulated in the liver, duodenum, and 
ileum.  This was consistent with early data demonstrating increased cholesterol 
synthesis in the liver and small intestine [9, 111], and increased Hmgcr activity in 
the liver during lactation [86, 112].  As the cholesterol biosynthetic genes are 
collectively controlled by sterol response element regulatory element binding 
protein 2 (Srebp-2), a very likely mechanism for increased mRNA production of 
the cholesterol biosynthetic enzymes was increased Srebp-2 activity.    
 As the cholesterol biosynthetic genes are all controlled by the transcription factor 
Srebp-2, the activity of Srebp-2 in hepatocytes, enterocytes, and mammary 
epithelial cells could prove useful in characterizing how gene expression is 
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controlled during lactation.  As there is some overlap between targets of the 
Srebp proteins [87], the activities of Srebp-1a and Srebp-1c should also be 
investigated.  In addition, Srebp-1a and Srebp-2 can form a heterodimer, and 
activity of the heterodimer may also be relevant in the tissues studied [182, 183].  
It has been proposed that in the lactating mammary gland, exposure to prolactin 
activates Akt, which in turn results in increased amounts of nuclear Srebp-1c 
[184].   
Nuclear amounts of Srebp-1a, Srebp-1c and Srebp-2 can be determined by 
Western analysis of  nuclear extracts of the tissues of interest [185] (in this case 
the hepatocyte and enterocytes from each part of the small intestine.)  Srebp-1c 
has also been specifically identified in the nuclear extracts of rat hepatocytes by 
Western blot [186].   
Slc39a4 shows increased mRNA in the gastrointestinal tract of lactating 
dams 
In addition to utilizing pathway analysis through Ingenuity Pathways, genes were 
grouped according to where in the gastrointestinal tract they display differential 
gene expression.  The zinc transporter Slc39a4 was in the list of genes 
upregulated in the liver, duodenum, jejunum, and ileum. 
Increased Slc39a4 is consistent with reports of increased zinc uptake during 
lactation in rats [76] and humans [73, 74].  As Slc39a4 is the major, although not 
only route through which zinc is absorbed in the small intestine [132], its 
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increased expression during lactation provides a likely mechanism for increased 
zinc absorption.   
Here, we hypothesize that increased expression of active Slc39a4 on the apical 
domain of enterocytes is responsible for the improved zinc absorption observed 
during lactation.  First, if the increase in Slc39a4 is leading to increased 
absorption, then the increase is likely happening at the level of protein as well, 
and this should be detectable on the apical membrane of enterocytes by Western 
blot and immunohistochemistry [187].  Because increased mRNA levels were 
detected in the microarray, it is worth detecting if the relative amounts of Slc39a4 
protein are consistent with the level of gene expression detected in the 
microarray. Under conditions of sufficient zinc concentration, Slc39a4 is rapidly 
degraded.  Therefore, it would be important to analyze levels of the protein 
throughout the day in order to detect if and when protein levels are altered.  In 
addition, because intracellular zinc concentration regulates stabilization of 
Slc39a4 mRNA and protein, dietary intake of could be monitored in order to 
compare presence of Slc39a4 protein relative to the amount of zinc consumed in 
the diet.     
The ileum expresses increased differential alternative splicing in lactating 
animals compared to the liver, duodenum, and jejunum 
Utilization of a two-way ANOVA for probeset effect and physiologic state effect in 
Partek (Partek Incorporated, St. Louis, Missouri)  resulted in detection of a much 
higher number of positive tests for the interaction term in the ileum (89) than in 
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the liver, duodenum, and jejunum (less than 20 in each tissue).  A positive test 
was indicative of differential alternative splicing, suggesting that regulation of 
differential splicing differs in the ileum relative to the other tissues.   Currently, we 
do not have an explanation regarding what could be regulating differential 
splicing in the ileum.   
The models for Analysis of Splicing Variance (ANOSVA) and Microarray 
Detection of Differential Alternative Splicing (MiDAS) overestimate p-values 
Histograms of p-values for both ANOSVA in Partek and MiDAS indicated a bias 
toward p-values at one (1), rather than p-values being uniformly distributed when 
not significant.  This bias has been indicated in the literature [109] and suggested 
that the models do not accurately reflect the data.  We propose the following 
workflow to evaluate the current existing methods for differential analysis of 
alternative splicing.   
Considering that both linear models (ANOSVA and MiDAS) appear to 
overestimate p-values, as shown by our own data and reported elsewhere [97, 
109], perhaps a parametric statistical model is not optimal for identifying locations 
of alternative splicing.  Regarding non-parametric tests, a Rank Product 
approach has been applied, but it is computationally demanding at the gene level 
[109].  In addition, although corporate software such as JMP Genomics and 
Partek allow for some filtering steps to be readily applied, such as specifying a 
metaprobeset file which defines which of Affymetrix’s confidence levels are used 
and setting a minimal intensity filter, other filtering steps need to be applied 
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manually.  For example, Affymetrix suggests that probesets with intensities that 
are higher than the constitutively expressed exons are likely cross-hybridizing 
with cDNA other than the expected target [97].  Validation rates through RT-PCR 
in published literature range from less than 50% [188] to above 80% [110] .  This 
clearly indicates the need for effective filtering to remove genes that appear to 
test positive for various reasons, but are not differentially alternatively spliced.  
Note that the phrase “differentially alternatively spliced” is used loosely, as 
calculations are based on a measurement of exon intensity relative to gene 
intensity.  Consequently, events such as alternative transcription start sites and 
polyadenylation site usage will also be detected as “alternative splicing”.   
A front end package that allows the user to readily apply various filtering 
algorithms as well as run a variety of statistical measures for differential 
alternative splicing would prove very useful.  We propose the following workflow 
to integrate the existing methods for detection of alternative splicing into one 
package (Figure 5.1).  It has been proposed that utilizing multiple methods and 
selecting the overlapping region of significant genes reduces the risk of false 
positives [109], so providing a package that reports the results from these tests 
and is able to generate a Venn Diagram of the overlapping regions of different 
tests could prove useful.  Although software such as JMP and Partek exist, these 
software packages tend to rely on an ANOVA model to detect differences in 
differential alternative splicing. 
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The first step to analyzing the microarray alternative splicing data  is allowing the 
software to access the data.  There are two possible situations in which an 
investigator may wish to import the data.  In the first case, the investigator has 
raw files directly following analysis of a dataset.  In the second case, the  
investigator has already converted the data into a workable format (for example, 
by running RMA) and simply wishes to import the data as a spreadsheet.  In the 
first case, various options for background correction, normalization, and 
summarization should be available.  Note that the option to not summarize the 
data, but rather work with the probe level data should be available in case the 
experimenter wishes to work directly from this data [189].  It is important that we 
include options for RMA when importing (RMA background correction, quantile 
normalization, and median polish) although other options may be included such 
as median normalization, and Tukey’s biweight for summarization.  Note that 
separate code would probably need to be written for each platform when 
importing raw data files, as each company uses its own file format.  
Consequently, it may be simpler to assume that the experimenter has the data 
already transformed and ready to be analyzed in a .txt format, in which case the 
data can be input as a large matrix.  In order to perform all of the previously 
described algorithms, data need to be available at the probe level, probeset (or 
exon) level, and gene level, meaning three datasets ultimately need to be input, 
in addition to a file that relates the multiple datasets.  For Affymetrix datasets, this 
is the cel design file (cdf), but a table with three columns (probe identifier, 
probeset (or exon) identifier, and gene identifier) should be sufficient and readily 
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available with a small amount of work for most experimenters on most platforms.  
Also, it should be worthwhile to note that information other than expression 
measurements may wish to be imported, such as DABG p-values for Affymetrix 
datasets for the purposes of filtering out poorly expressed probesets.  When 
importing, investigators should be asked which values are associated with 
microarrays, which microarrays are associated with respective treatment groups, 
and which columns include other data. 
Filtering data is an essential step in removing false positives, as nearly all 
methods for detecting differential splicing events run into similar problems with 
genes that are poorly expressed in a single group, exons that are poorly 
expressed in all groups, and probes that cross-hybridize.  Affymetrix has a series 
of recommended filtering procedures [97], but finding software that readily 
applies all of the available filters is difficult.  Through spreadsheet manipulation, 
the filters can be applied in JMP Genomics (SAS Institute Inc., Cary NC) or Excel 
(Microsoft Corporation), but a streamlined approach has not been taken for many 
of the possible filters.  Filtering out genes that are poorly expressed in either 
group, exons that are poorly expressed in all groups, and probesets that are 
likely to cross-hybridize are all essential [97].  Presence/absence calls can be 
made based on a value in a column being greater than or less than a specified 
number.  For example, one could make a first set of presence/absence calls 
under the conditions where if intensity for a given exon on a chip>3, then that 
exon on that chip is present; otherwise the exon is absent.  We could do the 
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same for DABG values (if DABG<0.05 then present, otherwise is absent).  The 
“cross-hyb type” column in the Affymetrix annotation files indicates whether or 
not a probe is predicted to cross-hybridize with non-target cDNA.  If cross-hyb 
type does not equal one (which is defined as not likely to cross-hybridize to non-
target cDNA), then an absence call can be made for that probe on all chips, 
indicating that the respective exon is to be filtered out.  Affymetrix’s 
recommendation for applying a presence/absence call for gene level data is 
whether 50% of the exons are present, so a presence/absence call could be 
made from the probeset level data accordingly.  Under normal circumstances, a 
gene should be removed if it is not expressed in any group, and a probeset/exon 
should be removed if none of the groups express the probeset/exon.   
Both JMP Genomics and Partek rely on a two-way ANOVA method for detection 
of differential splicing analogous to the ANOSVA method.  However, other 
methods exist including MiDAS [97], FIRMA [108], PECA-SI [189], and analysis 
of the rank products of splicing indices or intensities [109].  R-code exists for 
these methods, and given the open-source nature of R, these codes could be 
edited with credit to the original authors [108, 109, 189].   Ideally, software would 
ask the investigator which method should be applied and then analyze the 
corresponding method.  Like many other steps, clever spreadsheet manipulation 
makes these methods technically available using other software, although code 
to run these methods has not been specifically written for the spreadsheet 
management software.  However, organizing the methods so that they are 
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readily executable would be a useful tool.  Following analyses, spreadsheet 
software or the proposed software should be able to generate a Venn diagram of 
genes that test positive at various cutoffs (either raw p-values or FDR correcting 
methods can be used) from the various output files.  Note that many of these 
steps are computationally intensive, so managing how memory is used could 
become an issue.  Ideally, this should give a mechanism for readily comparing 
the large number of methods for detecting alternative splicing that exist.  The 
overall workflow can be found in Figure 5.1.   
An alternative transcript was detected for Abcg8 in the lactating liver 
Abcg8, part of a heterodimer that transports cholesterol into bile, shows 
decreased mRNA in the liver of lactating rats [93, 164], and functional Abcg8 
protein is not detectable in the hepatocytes of lactating dams [93].  In preliminary 
analysis of the alternative splicing dataset, Abcg8 was identified as a likely 
candidate for differential alternative splicing in the liver of lactating dams.  We 
therefore ran RT-PCR on the liver samples and isolated a band that was unique 
to a clone in lactating liver.  Sequencing revealed that a region that begins in part 
of exon four and ends in part of exon nine was spliced out in the splice variant.  
This further indicated part of the control of Abcg5/Abcg8 activity in the liver in 
lactating rats is controlled at the mRNA level.     
Possible differential alternative splicing in the renin-angiotensin system 
was detected in the ileum 
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Analysis of the list of genes that tested positive in the ileum by DAVID [105] 
resulted in identification of the renin-angiotensin as being a candidate for 
differential regulation in lactation through alternative splicing.  Of the four genes 
detected to be differentially alternatively spliced in Partek, one, angiotensin 
converting enzyme 2 (Ace2) had the lowest alternative splicing p-value amongst 
any gene in the dataset.  Ace2 is important in inhibiting the renin-angiotensin 
pathway, so validating the presence of the detected splice variant, and 
characterizing if it has altered function would be useful in describing the renin-
angiotensin pathway in the lactating rat.   
Future work: Characterization of Differences in Gene Expression in the 
liver Throughout Pregnancy and Lactation 
Our present work identified differences in gene expression in the liver and small 
intestine of lactating rats compared to age matched virgin controls at day 10 
postpartum, 16 h.  This only characterizes the difference in gene expression 
relative to controls at one specific time point.  One important question would be 
how the changes identified in lactating rats at this time point differ from changes 
at other time points.  For example, our laboratory has identified that day 10, 16h 
is the first point at which Cyp7a1, the rate limiting step for bile acid synthesis, 
shows a statistically significant increase in mRNA expression [10].  However, we 
have noted a number of physiologic differences regarding expression of hepatic 
bile acid transporter in early (day 2 postpartum) lactation [82].  Taking samples 
across several stages in lactation and pregnancy would allow an investigation for 
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when changes in gene expression begin and end.  If trends in gene expression 
are associated with specific pathways or transcription factors, this would also 
allow characterization of the roles of these pathways during lactation.  We 
propose measuring gene expression through microarray at the following time 
points: virgin (16 h), early pregnancy, late pregnancy, early lactation (day 2 
postpartum, 16 h), middle lactation (day 10 postpartum, 16h), and late lactation.  
Following the previous pooling scheme of four replicates per group and four 
individual rats composing a single replicate may lead to an excessive number of 
required rats (4 rats X 4 replicates X 6 groups = 96 rats).  The absence of a 
pooling scheme would result in higher variance amongst individuals, meaning 
that the statistical power would be based solely on the four replicates.  A possible 
compromise would be to reduce the number of rats pooled in a sample to three, 
requiring a total of 72 rats for the entire experiment.  We chose to focus on the 
liver because of its role in regulating bile acid synthesis, metabolizing 
xenobiotics, as well as being a major site of cholesterol biosynthesis.  Similar 
experiments have been performed in the mammary gland of pregnant and 
lactating mice [184, 190].  If we choose to only analyze a specific pathway, such 
as the cholesterol biosynthetic pathway, a small custom chip or nanostring 
experiment would be more efficient, and statistical power would be improved by 
reducing the number of genes queried. 
A one-way ANOVA model would be used for the purposes of determining 
statistical significance of each gene, with time being treated as a class variable.  
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The overall ANOVA would initially be fitted to an FDR of 0.2.  Genes that pass 
the initial test will need to be tested for pairwise comparisons between the 
respective time points.  To simplify comparisons, we would only consider the 
differences of each time point relative to the virgin controls.  This reduces the 
number of pairwise comparisons performed for each positive testing gene from 
15 to 5.  We currently propose a significance cutoff of p<0.0020 for the statistical 
contrasts, but both this value and the FDR may need to be adjusted based on the 
size of the list of significant genes.  (The p-value for contrasts within a gene is 
based on a modification of the Bonferroni procedure at α=0.01, as 
0.01/5=0.0020).  If the list is not sufficiently large, then pathway analysis 
becomes difficult.    Statistical pattern matching could then be used to assign 
genes to groups.  Each time point other than the virgin time point could be 
assigned to increased, no detectable change, or decreased relative to virgins for 
each gene.  For the purposes of pattern matching, the pairwise comparison p 
value cutoff may need to be relaxed to p<0.05, but only if the gene was 
previously defined as differentially expressed.  This is caused by the fact that a 
false negative would lead to assignment of a gene to a separate group.  
Characterization of these groups should give an indication as to when genes 
increase and decrease expression during pregnancy and lactation, and could 
lead to identification of signaling pathways that mediate changes in gene 
expression.   
Conclusion 
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We showed through microarray studies increased mRNA of cholesterol 
biosynthetic genes in the liver and small intestine and a likely mediator of 
increased zinc uptake (Slc39a4).  We propose that increased Srebp activity, 
particularly Srebp-2 is involved in the increased cholesterol synthesis detected in 
the liver and small intestine of lactating dams. In addition, we propose that the 
difference in expression in Insig in the small intestine and Scap in the liver 
causes the more dramatic increase in cholesterol synthesis in the liver relative to 
the small intestine.  Further work needs to be done to elucidate the mechanisms 
regarding how these changes in mRNA influence the physiology of the lactating 
animal.  In addition, we have proposed candidates for differential alternative 
splicing between lactating animals and virgin controls and have detected a splice 
variant of Abcg8 in the livers of lactating animals.  We also identified a possible 
splice variant for Ace2 in the ileum that requires verification.  Depending on the 
function of the splice variant, the Ace2 variant may influence sodium absorption 
and blood pressure in the lactating animal.  A number of additional studies can 
be performed, both to further characterize alternative splicing in more detail, and 
to elucidate how the detected changes in gene expression and alternative 
splicing influence the physiology of the lactating animal.   
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Figure 5.1: Workflow for detection of differential alternative splicing.  Data are 
initially imported and saved as gene level, probeset level (exon level), and/or at 
the level of individual probes, depending on the summarization method used.  
From here, data that would likely contribute to false positives are filtered out.  
Following the filtering algorithm, various methods can be applied to analyze the 
datasets, calling up filtered data at the appropriate summarization levels (gene, 
probeset, or probe) as input.  Venn diagrams can be used to compare results 
across the various methods by cross-referencing which genes, and in some 
cases exons, test positive by the various tests.   
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Appendix A: List of Abbreviations 
Prl-Prolactin 
Abc-Adenosine Triphosphate Binding Cassette 
Thra- Thyroid receptor alpha 
Thrb-Thyroid receptor beta 
Klf9-Kruppel like factor 9 
TRα1-Thyroid receptor alpha isoform 1 
TRβ1-Thryroid receptor beta isoform 1 
T3-triiodothyrodine 
PI3K-phosphoinositide 3 kinase 
AKT- v-akt murine thymoma viral oncogene homolog 
PIP2-Phosphotidyl inositol 4,5 bisphosphate 
PTEN-Phosphotase and tensin homolog 
PDK1-Pyruvate dehydrogenase kinase 1 
FOXO-Forkhead box transcription factor 
mTOR- Mechanistic target of rapamycin 
4EBP1-Eukaryotic initiation factor 4E binding protein 1 
PEPCK-Phosphoenolpyruvate carboxykinase  
G6P-Glucose 6 Phosphotase 
AMPK-Adenosine monophophate kinase 
Hmgcr-3-Hydroxy-3-methylglutaryl Coenzyme A reductase  
Glut4- Glucose transporter 4 
Acc-Acetyl-Coa Carboxylase 
CRTC2-CREB regulated transcription coactivator 2 
SREBP-Sterol regulatory element binding protein 
Ppargc1α-Ppar gamma coactivator 1α 
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JAK-Janus Kinase 
STAT-Signal transducer and activator of transcription 
Prlr-Prolactin receptor 
SR-Serine arginine 
Slc-Solute carrier 
Cyp-Cytochrome P450 
Erk-Extracellular signal related kinase 
Asbt- Apical sodium dependent bile acid transporter 
Ntcp- Sodium taurocholate cotransporting polypeptide 
Srebf- Sterol regulatory element binding factor 
Scap-SREBP chaperone 
Ugt- UDP glucuronosyltransferase  
DNA-Deoxyribonucleic acid 
RNA-Ribonucleic Acid 
RMA-Robust multichip averaging 
ANOVA-Analysis of variance 
FWER-Family wise error rate 
FDR-False Discovery Rate 
PFP-Proportion of false positives 
DAVID-Database for annotation visualization and integrated discovery 
EST-Expressed sequence tag 
MiDAS-Microarray detection of alternative splicing 
FIRMA-Finding isoforms through robust multichip averaging 
ANOSVA-Analysis of splicing variance 
DABG-Detection above background 
Ace2-Angiotensin converting enzyme 2 
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Ostα/β-Organic solute transporter alpha/beta 
Bsep-Bile salt export pump 
FGF-Fibroblast growth factor 
Fgfr-Fibroblast growth factor receptor 
RT-PCR-Reverse transcriptase polymerase chain reaction 
Rg9-mtd2- RNA guanine-9 methyltransferase domain containing 2 
KEGG-Kyoto Encyclopedia of genes and genomes 
Ch25h-Cholesterol-25 hydrolase 
Akr1d1-Aldo keto reducatase family 1 member d1 
Acox2-Acetyl-CoA oxidase 2 
Scp2-Sterol carrier protein 2 
Baat-Bile acid-CoA:amino acid N-acyltransferase 
IPA-Ingenuity Pathways Analysis 
CD28-Cluster of differentiation 28 
IL-2- Interleukin 2 
Insig-Insulin induced gene 
Scd2-Stearoyl-Coenzyme A desaturase 2 
ME1- Malic enzyme 1 
Ctsb-Cathepsin B 
Tmbim6-Transmembrane BAX inhibitor motif containing 6 
Tmed2-Transmembrane emp24 domain trafficking protein 2 
Tmem97-Transmembrane protein 97 
NPC1l1-Niemann Pick 1 like 1 
Fdft1-Farnesyl-diphosphate farnesyl transferase 1 
Mvk-Mevalonate Kinase 
Pmvk-Phosphomevalonate kinase 
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Mvd-Mevalonate decarboxylase 
Idi1-Isopentyl-diphosphate delta isomerase 1 
Sqle-Squalene epoxidase 
Lss-Lanosterol synthase 
Dhcr7-7-dehydro cholesterol reductasse 
BLAT-BLAST like alignment tool 
UCSC-University of California, Santa Cruz 
Anpep-Alanyl aminopeptidase 
Lnpep-Leucyl/cystinyl peptidase 
Mme-Membrane metallo-endopeptidase 
Ahr-Aromatic hydrocarbon recptor 
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